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 GPR35, a G protein-coupled receptor (GPCR), was discovered and specified as an 
orphan receptor in 1998. GPR35 has been described as a prospective therapeutic target as 
a result of its association with many diseases including type-2 diabetes, nociceptive pain, 
inflammation, mild mental retardation syndrome, metabolic disorders, and gastric cancer. 
A GPR35 antagonist benzothiazole was identified via high-throughput screening of 
approximately 300,000 compounds. Based on the docking of the benzothiazole into a 
homology model of GPR35, analogs were designed, synthesized, and evaluated as 
antagonists at GPR35. The study examines various regions of the GPR35 binding site for 
the benzothiazole ligand. The results provided information that was used as a guide to 
design and synthesized potent GPR35 ligands. 
A heterocyclic ring, pyrazole, has gained special consideration as a result of its 
significant biological properties including anti-cancer, anti-microbial, anti-bacterial, anti-
fungal, and anti-inflammatory. Structurally novel pyrazole derivatives were designed, 
synthesized and evaluated for antagonist activity at the GPR35 receptor. Due to the 
scarcity in the anti-microbial drugs and limited scaffold with potentially unique mode of 
action and different resistance mechanism, these pyrazoles were also evaluated for their 
anti-microbial activity. SAR study on the pyrazole core presented potential antimicrobial 
agents that will serve as basis for designing and developing novel antimicrobial drugs.  
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CHAPTER I 
 
DESIGN, SYNTHESIS, AND EVALUATION OF GPR35 AGONISTS 
 
Introduction 
  G protein-coupled receptors (GPCRs) represent the largest family of proteins in 
the mammalian genome.
[1]
  There are two major characteristics associated with GPCRs. 
First, all the receptors interact with G-protein. Second, all the receptors consists of seven 
α-helices imbedded in the cell membrane. The endogenous ligands for GPCRs are 
considerably diverse, including proteins, lipids, peptides, amines, nucleotides, and 
hormones.
[1]
  These ligands bind to the GPCRs and trigger a series of reactions with 
multiple alternative signaling pathways to ultimately deliver the messages and generate 
the appropriate physiological responses. More than half of today’s drugs are targeted at 
GPCRs which reflect the physiological and pharmacological importance of these 
receptors.
[2]
   
  Cloning and sequencing of the human genome led to the discovery of new 
GPCRs, however, many of the GPCRs are still orphan receptors. By definition, an orphan 
receptor is a receptor that lacks the identification of endogenous ligands.
[3]
  GPR35 was 
discovered and specified as an orphan receptor in 1998 using molecular cloning 
techniques.
[3]
 The study described and assigned the signal of GPR35 to chromosome 2, 
region q37.3.  Initially, GPR35 was discovered as an open reading frame encoding a 
protein of 309 amino acids. The sequence of these amino acids showed the identity of 
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GPR35. GPR35 sequenced amino acids resembled amino acid sequences of many 
receptors including nicotinic acid receptor HM74, nucleotide receptors P2Ys, GPR27, 
and GPR55.
[1, 3] 
  First detection of GPR35 was in the rat intestine.
[3]
  High levels of GPR35 were 
detected in gastrointestinal tissue and immune cells.
[4]
  Significant expression of human 
GPR35 were reported in small intestine, colon, spleen and immune cells; with lower 
levels of GPR35 reported in heart, pancreas, kidney, liver, and adipose tissues.  
  Although limited information on GPR35 has appeared and some certainty might 
change when the crystal structure of GPR35 is determined, the discovery of a GPR35 
endogenous ligand has been confirmed.  A metabolite of amino acid L-tryptophan, 
kynurenic acid, was reported as the first endogenous ligand for the GPR35 receptor with 
a moderate to low potency agonist activity.
[4]
  The moderate potency of kynurenic acid 
makes deorphanization of the GPR35 still under debate. 2-Acyl lysophosphatidic acid 
(LPA) was also described as another endogenous ligand for the GPR35 receptor.
[5]
 
Zaprinast, a well characterized cyclic guanosine monophosphate-specific 
phosphodiesterase inhibitor, was described as a first-rate GPR35 exogenous ligand that 
moderately activates human GPR35
[6]
 (Table 1). 
  Since GPR35’s discovery, it has attracted a lot of attention in the area of drug 
design and development. In 2000, GPR35 has been suggested to have significant role in 
type-2 diabetes.
[7]
 Genome-wide screening of type-2 diabetes genes reported linkage 
between the disease and GPR35. Association of GPR35 with type-2 diabetes was 
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dependent on the finding of 19 polymorphisms in GPR35 region and 4 in the intergenic 
region of GPR35. 
 
Table 1 
 
GPR35 Endogenous and Exogenous Agonists 
 
Agonist Structure EC50 
LPA 
 
_ 
 
Kynurenic acid 
 
217 µM 
cGMP 
 
131 µM 
Reverse T3 
 
100 µM 
DHICA 
 
22 µM 
4 
 
 
Table 1 
(Cont.) 
 
Agonist Structure EC50 
Furosemide 
 
8.3 µM 
Tyrphostin-51 
 
8 µM 
Zaprinast 
 
8 µM 
Cromolyn 
 
7 µM 
Amlexanox 
 
4 µM 
5 
 
 
Table 1 
(Cont.) 
 
Agonist Structure EC50 
Pamoic acid 
 
50 nM 
Compound 1 
 
26 nM 
Bufrolin 
 
13 nM 
PSB-13253 
 
12 nM 
6 
 
 
Table 1 
(Cont.) 
Agonist Structure EC50 
Lodoxamide 
 
4 nM 
  
 GPR35 is proposed to be strongly involved in pain signaling.
[8]
 Based on the 
expression of GPR35 in the rat nociceptive neurons and the involvement of GPR35 in 
antinociceptive mechanism, the study demonstrated that GPR35 might be a novel 
therapeutic target for nociceptive pain. 
 High expression of GPR35 in immune cells hints at linkage between GPR35 and 
immune response. Although the potential role of GPR35 in immunomodulation remains 
unexplored, involvement of this receptor in inflammation response has been confirmed.
[4]
 
The study connected an elevated level of kynurenic acid during inflammation and 
involvement of GPR35 in inflammation. A number of subsequent studies linked GPR35 
with inflammatory regulation,
[9]
 inflammatory macrophage,
[10]
 and inflammatory bowel 
disease.
[11]
 
 GPR35 has been suggested as a prospective therapeutic target in the treatment of 
cardiovascular diseases. Linkage between the GPR35 and heart failure was determined 
via screening study of 12 genes in rat cardiomyocytes.
[12]
 Another screening study using 
single nucleotide polymorphisms strongly linked GPR35 with coronary artery disease.
[13]
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GPR35 has been suggested to have a significant role in Albright hereditary 
osteodystrophy and mild mental retardation syndrome associated with the deletion on 
chromosome 2q37.3.
[14]
 GPR35 has also been suggested to be involved in metabolic 
disorders,
[15]
 asthma,
[16]
 and gastric cancer.
[17]
 
 Association of GPR35 with that number of diseases urges the need to characterize 
the GPR35 receptor, to define the chemistry and biochemistry of this receptor, to regulate 
this receptor, and to ultimately provide compounds that utilize this information for 
potential therapeutic advantages. As a consequence, many studies focus on the synthesis 
of new compounds with agonist activity on GPR35 to reach this goal.
[18, 19, 20, 21]
 Table 1 
showed numbers of endogenous and exogenous ligands act as moderate to potent agonists 
at GPR35.
[21]
 For instance, similar to zaprinast, furosemide, tyrphostin-51, cromolyn, and 
amlexanox showed moderate agonist activity at GPR35. Until recently, pamoic acid was 
significantly more potent than the endogenous and synthetic GPR35 agonists with an 
EC50 of 50 nM (Table 1). However, thus far, these endogenous and synthetic ligands have 
proved ineffectual in characterizing GPR35 receptor due to moderate potency or poor 
selectivity. For these reasons, pamoic acid was selected as a lead to develop more potent 
and selective agonists of human GPR35 receptor. The proposed hypothesis is constructed 
to attain extremely potent and selective GPR35 agonist for therapeutic targets and radio 
labeling purposes which will facilitate the characterization of the GPR35 receptor.  
Modeling of GPR35 Active State 
Although the crystal structure of GPR35 is not available, the Reggio group was 
able to build a homology model of GPR35 based on known crystal structure of other 
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related GPCRs. This homology model can be used to spot the ligand binding site for 
GPR35 and identify the amino acid interactions when the ligands bind to the receptor as 
well as supporting the therapeutic potential for GPR35. Construction of the GPR35 
homology model is discussed in detail in Chapter II. However, the focus of this chapter is 
the modeling of the active state of the GPR35.  
The GPR35 active state was built based on a sequence comparison with the β2-
adrenergic receptor.
[23]
 In the GPR35 active form intracellular and extracellular loops 
were modified to mimic the class A conserved disulfide bridge. The activated state model 
was generated to maintain the hydrogen bonds, loops and termini. Also the helicity was 
kept using the harmonic constraint on the backbone. Finally, the loops were energy 
minimized using the conformational memories technique.  
Design of GPR35 Agonists 
There have been a considerable number of studies focusing on the screening of 
chemical libraries in an attempt to identify potential GPR35 ligands.
[19, 22]
 The chemical 
library of Prestwick has been broadly targeted for the aim of identifying potential GPR35 
ligands. From the screening of 1120 small molecules in the Prestwick chemical library, 
Dr. Mary Abood and coworkers discovered new and potent GPR35 ligands.
[22]
 Pamoic 
acid, a well-known and presumably inactive drug ingredient, was revealed to have 
GPR35 agonist activity. The study disclosed that pamoic acid effectively recruits β-
arrestin2 to GPR35 and activates ERK1/2. The study also demonstrated that pamoic acid 
is more potent than any other known ligands, endogenous or exogenous, for GPR35 with 
an EC50 of 50 nM.  
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Despite the fact that pamoic acid was reported as the most potent GPR35 
exogenous ligand, it is still not ideal as a radioligand due to non-selectivity and moderate 
potency. For these reasons the collaboration between our departments’ labs and Dr. Mary 
Abood selected pamoic acid for initial compound development in order to achieve a more 
potent and selective GPR35 agonist and ultimately provide means to characterize GPR35.  
As pamoic acid deprotonated readily in physiological pH (pka1 = 2.51, pka2 = 3.1), 
the lowest energy conformation was calculated for the dianionic form of pamoic acid.
[23]
 
Interaction of the binding site of activated form of GPR35 with the pamoic acid was 
examined based on the deprotonated pamoic acid. Pamoic acid binding pocket is located 
mainly in TMH3, 4, 5, and 6 region of the GPR35 activated form. Pamoic acid provides a 
handful of favorable interaction with the residue of the binding site. Due to the 
deprotonation of pamoic acid, the arginine residue was considered the main contributing 
residue. The residues R4.60(151), R3.36, R(164), and R(167) provide a salt bridge with 
the carboxylic acid moieties of pamoic acid. Residues R(164), Q3.29 and S5.39 provide 
hydrogen bonding also with carboxylic acid moieties. The residues T166, L6.55, and 
L3.33 provide van der Waals interactions with the pamoic acid. Finally R4.60 form 
cation-π interactions with the fused ring of pamoic acid (Figure 1). These interactions of 
pamoic acid with the GPR35 binding site supported our selection of pamoic acid as a lead 
for this study.  
About eight analogs of pamoic acid were subjected to computational analysis in 
the Reggio lab to predict the interaction, or the lack of interaction, at the binding site of 
the GPR35 model activated form (R*). Three compounds show proper fitting into the 
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binding pocket of GPR35 model (R*). Figure 2 shows pamoic acid and the three selected 
analogs 1.1, 1.2, and 1.3. Analog 1.1 lacks the hydroxyl groups on the naphthalene rings 
while analog 2 has additional methoxy groups at position 7 of each naphthalene ring. 
Analog 1.3 has two methyl groups at the methylene position of the pamoic acid. 
 
Figure 1. Docking of Pamoic Acid in the GPR35 Homology Model Active State. 
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Figure 2. Pamoic Acid and Analogs 1.1, 1.2 and 1.3. 
 
Synthesis of Pamoic Acid Analogs 
The proposed synthesis of analog 1.1 is shown in the retrosynthesis scheme 
(Figure 3). The synthetic route includes replacement of the hydroxyl groups of pamoic 
acid with triflate groups using triflic anhydride and then reduction using palladium and a 
reducing agent.  
 
Figure 3. Retrosynthesis Analysis of Analog 1.1. 
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The synthesis of analog 1.1 initiated with treating commercially available pamoic 
acid with triflic anhydride and pyridine to produce compound 1.4 (Figure 4). However, 
the intended product was not observed which is assumed to be due to the presence of 
carboxylic acid groups. Esterification of the carboxylic acid groups of pamoic acid to 
obtain ester 1.5 was then suggested as a solution. Because pamoic acid possesses multiple 
OH functionalities, esterifiction of pamoic acid proved to be ineffectual (Figure 4). As a 
result, another synthetic pathway was pursued.  
 
Figure 4. Unsuccessful Attempts to Synthesize Analog 1.1 Using Pamoic Acid. 
 
The synthesis (Figure 5) began with esterification of the commercially available 
3-hydroxy-2-naphthoic acid to form methyl 3-hydroxy-2-naphthoate 1.6 in high yield. 
The resulting methyl 3-hydroxy-2-naphthoate undergoes a condensation reaction with 
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formaldehyde to result in the formation of methyl pamoate 1.7.
[24]
 Methyl pamoate was 
then treated with triflic anhydride and pyridine to yield the ditriflate 1.8 in high yield.
[25]
 
The resulting product was then subjected to palladium-catalyzed reduction using formic 
acid as a reducing agent,
[26]
 thus effectively removing the hydroxyl groups in the original 
compound. Subsequent column chromatographic purification confirms the successful 
substitution of the triflates with hydrogens to form intermediate 1.9 in good yield (Figure 
5).  
 
 
Figure 5. Synthesis of Analog 1.1. (a) MeOH, H2SO4, 93% (b) HCOH, CH3CO2H, 85% 
(c) Tf2O, pyridine, CH2Cl2, 94% (d) Pd(OAc)2, PPh3, DMF, TEA, HCO2H, 69% (e) 
(CH3)4NOH, CH2Cl2, 92%. 
 
Although the last step in the synthesis seems to be simple deprotection of 
carboxylic acid to produce final analog 1.1, numerous attempted experiments resulted in 
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decomposition or recovery of the starting material (Table 2). As solubility was likely the 
cause of failure, tetramethylammonium hydroxide was attempted so that a nonpolar 
solvent could be used (Figure 5). 
The second analog (1.2) contains two methoxy groups at position 7 of each 
naphthalene ring. Analog 1.2 was synthesized using commercially available 3-hydroxy-7-
methoxy-2-naphthoate sodium salt (Figure 6). Because the 3-hydroxy-7-methoxy-2-
naphthoate ring comprises multiple activated positions including positions 4, 6, and 8 
(see the numbering system), the condensation reaction of 7-methyl-3-hydroxy-2-
naphthoate sodium salt with formaldehyde could produce a mixture of products.
[24]
 
However, position 4, which is activated by a hydroxyl group, is more active than position 
6 and 8 which are activated by methoxy groups. As a result, close monitoring of the 
reaction was required to successfully produce the desired product in 64% yield (Figure 
6).  
 
Table 2 
 
Experimental Condition for Deesterificaton Reaction 
 
Entry Reagent Result 
1 EtOH, CH2Cl2, NaOH, H2O starting material 
2 NaOH, MeOH starting material 
3 NaOH, H2O starting material 
4 LiOH, H2O starting material 
5 H2SO4, H2O starting material 
6 (Et)3BnNBr, CH2Cl2, NaOH decomposition 
7 (CH3)4NOH, CH2Cl2 desired product 
15 
 
 
 
Figure 6. Synthesis of Analog 1.2. 
 
Pamoic acid analog 1.3 required installation of two methyl groups at methylene 
position of pamoic acid. Numerous experiments were conducted including different 
routes. Specifically, a route incorporating condensation of acetone or acetone surrogates 
using 3-hydroxy-2-naphthoic acid or methyl-3-hydroxy-2-naphthoate turned out 
undesired products or the starting materials. Oxidation of the methylene position of 
pamoic acid followed by nucleophilic addition of the methyl groups was suggested as 
alternative route. However, the intended product was not synthesized (Table 3). The 
steric hindrance effect and the geometry of the product were expected to be the reasons 
for unsuccessful reactions.  
Results and Discussion 
The measurement of the agonist activity of the synthesized analogs was carried 
out using β-arrestin assay. The bioassay results showed that analog 1.2 was slightly less 
potent than the pamoic acid. Whereas, removing the hydroxyl groups from position 3 in 
analog 1.1 diminished the activity of pamoic acid (Table 4). 
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Table 3 
 
Unsuccessful Trails to Synthesize Analog 1.3 
 
 
Starting material Reagents Results 
3-hydroxy-2-naphthoic acid (CH3)2CO, CH3COOH 
Undesired 
product 
3-hydroxy-2-naphthoic acid (CH3)2CO 
Starting 
material 
3-hydroxy-2-naphthoic acid (CH3)2C(OCH3)2, CH3COOH 
Undesired 
product 
3-hydroxy-2-naphthoic acid (CH3)2C(OCH3)2, CH3COOH, H2SO4 
Undesired 
product 
Methyl-3-hydroxy-2-
naphthoate 
(CH3)2CO, CH3COOH 
Starting 
material 
Methyl-3-hydroxy-2-
naphthoate 
(CH3)2C(OCH3)2, CH3COOH 
Undesired 
product 
Methyl-3-hydroxy-2-
naphthoate 
(CH3)2C(OCH3)2, CH3COOH, H2SO4 
Undesired 
product 
Pamoic acid (Et)3BnNBr, KMnO4, DCM Decomposition 
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Table 3 
(Cont.) 
Starting material Reagents Results 
Pamoic acid Acetic anhydride, CrO3 
Starting 
material 
Pamoic acid (Bu)4NHSO4, KMnO4, DCM 
Starting 
material 
 
Table 4 
 
Biological Results of Pamoic Acid Analogs 
 
 
EC50 (nM) 
Pamoic acid 50 
Analog 1.1 604 
Analog 1.2 61 
 
Analysis of these results provides information on pamoic acid as an agonist ligand 
for GPR35. The result implies the significance of hydroxyl groups on position 3 of each 
naphthalene ring of pamoic acid. This probably indicates a type of interaction between 
the hydroxyl groups and the residue at the binding site of GPR35 or interaction of this 
hydroxyl groups with carboxylic acid functional groups. The slight decreasing of the 
potency of pamoic acid upon modifying position 7 suggests that this modification has 
low influence on the agonist activity. However, the binding site at this region of the 
receptor could prefer positively charged surfaces. As a result, a likewise response will 
emerge if the modification was performed at position 6 or 8.  
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The analysis of the bioassay indicates that the possibility of improving the 
potency or selectivity of pamoic acid is most likely limited. Additionally, numerous 
research groups are focusing on the identification and creation of novel and potent 
GPR35 agonists (Table 1). Milligan Group reached their goal with a novel and potent 
GPR35 agonist (EC50 = 26 nM).
[27]
 Whereas the Muller Group was able to synthesize a 
novel radio-labeled GPR.335 agonist with high potency (EC50 = 5.5 nM)
[28]
 (Figure 1.4). 
This approach is the basis to pursue a different but related unsolved dilemma. 
 
 
 
Figure 7. Potent GPR35 Agonists. 
 
Experimental Procedures and Characterization 
All anhydrous reactions were performed in oven dried glassware under a nitrogen 
atmosphere.  All commercial reagents and solvents were used without further 
purification. Chromatographic purification was performed using silica gel (60 Å, 32-
63μm). Analytical thin-layer chromatography (TLC) was performed on SiO2 plates and 
visualizing by UV irradiation at 254 nm. NMR spectra were recorded in CDCl3, DMSO-
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d6, methanol-d4, or acetone-d6 using JEOL ECA spectrometer (500 MHz for 
1
H, 125 
MHz for 
13
C). All 
1
H NMR experiments are reported in δ units, parts per million (ppm) 
downfield of TMS, and were measured relative to the signals for chloroform (7.26 ppm), 
DMSO (2.50 ppm), methanol (3.31 ppm), or acetone (2.05 ppm). All 
13
C NMR spectra 
were reported in ppm relative to the signals for chloroform (77 ppm), DMSO (39.5 ppm), 
methanol (49 ppm), acetone (29.8 ppm) and. Coupling constants, J, are reported in hertz 
(Hz) and multiplicities are listed as singlet (s), doublet (d), triplet (t), doublet of doublets 
(dd), triplet of doublets (td), quintet (quint), multiplet (m), etc. High resolution mass 
spectra were acquired on a Thermo Fisher Scientific LTQ Orbitrap XL MS system using 
electrospray ionization (ESI).  
To a solution of 3-hydroxy naphthalene-2-carboxylic acid (3.60 g, 19.1 mmol) in 
dry methanol (20 mL) was added concentrated sulfuric acid (0.22 mL) and the mixture 
was refluxed for 17 hours (Figure 8). The excess methanol was evaporated off under 
reduced pressure. The residue was then dissolved in ethyl acetate (50 mL), washed 
several times with 5% aqueous K2CO3 and brine, and then dried using Na2SO4. The 
product was crystallized as yellow crystal during solvent evaporation under reduced 
pressure (3.6 g, 93% yield). The product matched spectral data from reference 29.
[29] 
 
 
Figure 8. Synthesis of Methyl 3-hydroxyl-2-Naphthoate. 
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 Following a reported procedure,
[24]
 methyl 3-hydroxy-2-naphthoate (0.49 g, 2.47 
mmol) was dissolved in 37% aqueous formaldehyde (0.58 mL, 7.42 mmol) and glacial 
acetic acid (0.58 mL) and the mixture was refluxed at 110 °C for 17 hours (Figure 9). The 
product was cooled in an ice bath, filtered under vacuum, washed with cold water (125 
mL) and then with ethyl alcohol to produce the desired product (0.88 g, 85% yield).  
1
H NMR (500 MHz, CDCl3) δ 11.26 (s, 2H), 8.40 (s, 2H), 8.23 (d, J = 8.59 Hz, 2H), 7.69 
(d, J = 8.02 Hz, 2H), 7.33 - 7.38 (m, 2H), 7.19 (t, J = 7.16 Hz, 2H), 4.95 (s, 2H), 4.05 (s, 
6H). 
13
C NMR (126 MHz, CDCl3) δ 171.1(2C), 153.4 (2C), 137.3 (2C), 131.6 (2C), 130.0 
(2C), 129.0 (2C), 127.2 (2C), 124.3 (2C), 123.5 (2C), 121.9 (2C), 113.5 (2C), 52.8 (2C), 
20.6. 
HRMS (ESI): C25H21O6 [M+H]
+
, Calculated: 417.13381, Found:417.1327. 
 
Figure 9. Synthesis of Methyl Pamoate. 
 
 Following a reported procedure,
[25]
 to a solution of methyl pamoate (0.10 g, 0.24 
mmol) in dry dichloromethane (3 mL) under N2 atmosphere was added dry pyridine (0.10 
mL, 1.20 mmol) followed by triflic anhydride (0.12 mL, 0.72 mmol) and the mixture was 
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stirred at room temperature for 17 hours (Figure 10). Saturated solution of NaHCO3 (10 
mL) was added to the reaction mixture and the product was extracted with ethyl acetate, 
dried over Na2SO4, and evaporated off under reduced pressure to obtain 0.15 g of paige 
solid (94% yield).  
1
H NMR (500 MHz, CDCl3) δ 8.49 (s, 2H), 7.86 (dd, J = 3.44, 6.30 Hz, 2H), 7.82 (dd, J 
= 3.44, 6.30 Hz, 2H), 7.45 - 7.49 (m, 4H), 5.10 (s, 2H), 4.06 (s, 6H). 
13
C NMR (126 MHz, CDCl3) δ 165.2 (2C), 142.1 (2C), 134.2 (2C), 133.9 (2C), 131.5 
(2C), 130.1 (2C), 129.9 (2C), 129.4 (2C), 127.8 (2C), 124.3 (2C), 122.8 (2C), 53.0 (2C), 
24.8. 
HRMS (ESI): C27H19F6O10S2 [M+H]
+
, Calculated: 681.03238, Found:681.0311. 
 
Figure 10. Synthesis of Ditriflate 1.8. 
 
 Following a reported procedure,
[26]
 an oven dry round bottom flask was equipped 
with starting material (0.10 g, 0.15 mmol), palladium acetate (0.003 g, 0.015 mmol), and 
triphenyl phosphine (0.01 g, 0.03 mmol). Dry DMF (1 mL) and TEA (0.10 mL, 0.74 
mmol) were added at room temperature under N2 followed by formic acid (0.02 mL, 0.59 
mmol) and then the mixture was stirred at 100 °C for 17 hours (Figure 11). The mixture 
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was cooled to room temperature, brine (10 mL) was added and the product was extracted 
with ether, washed with brine, and dried over Na2SO4. The crude mixture was then 
evaporated and purified by column chromatography using solvent system of hexane and 
ethyl acetate (15/ 85) to obtain 0.039 g of white solid (69% yield).  
1
H NMR (500 MHz, CDCl3) δ 8.53 (s, 2H), 7.99 - 8.05 (m, 4H), 7.68 (d, J = 1.72 Hz, 
2H), 7.55 - 7.59 (m, 4H), 4.90 (s, 2H), 3.87 (s, 6H). 
13
C NMR (126 MHz, CDCl3) δ 167.3 (2C), 136.3 (2C), 134.3 (2C), 133.1 (2C), 130.6 
(2C), 130.5 (2C), 128.7 (2C), 127.2 (2C), 126.6 (2C), 126.3 (2C), 123.9 (2C), 52.3 (2C), 
35.8. 
HRMS (ESI): C25H21O4 [M+H]
+
, Calculated: 385.14398, Found:385.1068. 
 
Figure 11. Synthesis of Methyl Ester 1.9. 
 
 To a stirred solution of the methyl ester (0.21 g, 0.055 mmol) in DCM (2 mL), 
was added 25% solution of (CH3)4NOH (0.4 mL, 1.09 mmol) in methanol and the 
mixture was refluxed at 45 °C for overnight (Figure 12). The mixture was acidified to 
pH~2 using HCl (1M), extracted with DCM and washed with water many times. The 
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product was precipitated out of the DCM layer, collected by filtration and dried on high 
vacuum to yield 0.02 g (92% yield) of a white solid. 
1
H NMR (500 MHz, Acetone-d6) δ 8.61 (s, 2H), 8.22 (d, J = 8.02 Hz, 2H), 8.17 (d, J = 
9.17 Hz, 2H), 7.75 (s, 2H), 7.62 - 7.71 (m, 4H), 5.07 (s, 2H). 
13
C NMR (126 MHz, Acetone-d6) δ 166.2 (2C), 136.4 (2C), 133.8 (2C), 132.7 (2C), 
129.8 (2C), 129.7 (2C), 128.1 (2C), 127.0 (2C), 126.2 (2C), 125.6 (2C), 123.6 (2C), 34.5. 
HRMS (ESI): C23H17O4 [M+H]
+
, Calculated: 357.11268, Found:357.1119. 
 
Figure 12. Synthesis of Analog 1.1. 
 
Sodium 7-methoxy-3-hyroxy-2-naphthoate (0.50 g, 2.08 mmol) was dissolved in 
37% aqueous formaldehyde (0.51 mL, 6.24 mmol) and glacial acetic acid (0.51 mL) and 
the mixture was refluxed at 100 °C for 2 hours (Figure 13). The product was cooled in an 
ice bath and then filtered under vacuum, washed with cold water (125 mL) and then with 
cold ethyl alcohol.  Product was purified by silica gel column chromatography using a 
solvent system of ethyl acetate and methanol (90/10) to yield 0.60 g of the desired 
product (64% yield) as yellow solid.  
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1
H NMR (500 MHz, DMSO-d6) δ 11.80 (br. s, 2H), 8.34 (s, 2H), 8.00 (d, J = 9.16 Hz, 
2H), 7.28 (s, 2H), 7.03 (dd, J = 2.29, 9.16 Hz, 2H), 4.70 (s, 2H), 3.71 (s, 6H). 
13
C NMR (126 MHz, DMSO-d6) δ 173.1 (2C), 155.7 (2C), 152.4 (2C), 132.2 (2C), 130.4 
(2C), 128.3 (2C), 125.4 (2C), 122.0 (2C), 121.5 (2C), 114.8 (2C), 108.5 (2C), 55.6 (2C), 
20.5. 
HRMS (ESI): C25H21O8 [M+H]
+
, Calculated: 449.12364, Found:449.1179. 
 
 
Figure 13. Synthesis of Analog 2.2. 
 
 
NMR Spectra of Compounds 
 
MA-I-7-1H-1.jdf
11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
A
b
so
lu
te
 I
nt
en
s
ity
6.012.012.012.052.042.042.011.99
 
Figure 14. 
1
H NMR Spectra of Compound 1.7. 
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Figure 15. 
13
C NMR Spectra of Compound 1.7. 
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Figure 16. 
1
H NMR Spectra of Compound 1.8. 
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Figure 17. 
13
C NMR Spectra of Compound 1.8. 
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Figure 18. 
1
H NMR Spectra of Compound 1.9. 
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Figure 19. 
13
C NMR Spectra of Compound 1.9. 
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Figure 20. 
1
H NMR Spectra of Compound 1.1. 
 
28 
 
 
MA-I-28-13C-DELTA-1.jdf
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Figure 21. 
13
C NMR Spectra of Compound 1.1. 
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Figure 22. 
1
H NMR Spectra of Compound 1.2. 
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MA-I-23-13C-delta-1.jdf
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Figure 23. 
13
C NMR Spectra of Compound 1.2. 
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Introduction 
GPR35, a G protein-coupled receptor (GPCR), was discovered and classified as 
an orphan GPCR in 1998
[1]
 and deorphanized in 2006 by the discovery of kynurenic acid 
as the endogenous agonist.
[2] 
Since the discovery of GPR35, limited references on the 
GPR35 receptor have appeared and there is a scarcity of ligands, endogenous or 
exogenous, that regulate GPR35. The deorphanization of GPR35 receptor has even been 
debated due to the poor potency of kynurenic acid (EC50 of 39 µM). Recently, GPR35 has 
gained special consideration as a result of its association with many diseases including 
type-2 diabetes,
[3]
 nociceptive pain,
[4]
 inflammation,
[1]
 mild mental retardation 
syndrome,
[5]
 metabolic disorders,
[6]
 and gastric cancer.
[7]
 Based on the association of 
GPR35 with these major diseases and disorders, there is a current and urgent need for 
compounds to regulate the GPR35 receptor and to serve as research tools in molecular 
characterization of GPR35 receptor. In this chapter, we report an initial structure-activity 
relationship (SAR) study of GPR35 that was enabled by an inactivate state homology 
model. This research will assist in the design of potent and selective ligands that act as 
antagonists at GPR35.  
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Homology Model 
Only small numbers of GPCRs have been crystallized including, rhodopsin (Rho), 
meta-rhodopsin, β2-adrenergic receptor (β2-AR), β1-adrenergic receptor (β1-AR), 
adenosine (A2A) receptor, CXCR4, dopamine D3 receptor, and the Histamine H 
receptor.
[8]
 These crystal structures share fundamental topologies specifically; the seven 
transmembrane alpha helices (TMHs) arrange to form a closed bundle and connected 
with loops that extended intracellular and extracellular membrane surface with C-
terminus and N-terminus respectively. Finally, with exception of some crystal structures 
when ligand binding occurs within extracellular loops, ligand binding takes place in the 
TMH bundle. Sharing these topologies makes it possible to use a template crystal 
structure of crystallized receptors to build a homology model of un-crystallized receptor. 
Thus, it is possible to build a homology model of GPR35 based on available crystal 
structure.  This homology model can then be used to explore the GPR35 ligand binding 
pocket and key amino acid interactions for GPR35 ligands and will serve as a research 
tool or basis for designing and developing novel drugs. 
The construction of GPR35 homology model was done based upon sequence-
dictated differences with the template of β2-adrenergic receptor (Figure 24).
[9]
 These 
differences included TMH2, TMH4, TMH5, and TMH7. TMH2 has proline shift from 
P2.59 in β2-AR to P2.58 in GPR35 receptor. In GPR35 receptor TMH4 losses proline 
P4.60 and TMH5 has an additional proline P5.43. TMH7 has DAICY in GPR35 instead 
of NPXXY in β2-AR. Conformational memories were used to explore conformational 
differences in these helices dictated by sequence variations. The GPR35 inactive state 
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binding site is shaped for a long horizontal ligand with one end near TMH5 and the other 
reaching past TMH2 and TMH7. The pocket near TMH3, 4, 5 and 6 is larger than the 
pocket near TMH2 and TMH7. The narrow channel connecting the two pockets is 
bracketed by R6.58 above and Y3.32 below. 
 
Figure 24. Comparison between β2-AR Crystal Structure (A) and GPR35 Homology 
Model (B). 
 
Chemical Library Screening 
To date, there is no potent and selective GPR35 antagonist. The reported GPR35 
antagonist either nonpotent or nonselective. Table 5 shows the only reported antagonists.  
A screen performed with the Molecular Libraries Probe Production Initiative evaluated 
~300,000 compounds in an image-based high-throughput, high-content primary 
screen.
[10]
 This screen identified a few relatively potent and selective GPR35 antagonists, 
rhodanine 2.28 (CID2286812), pyrrazole 2.29 (CID2745684), benzothiazole 2.1 
(CID1231538), and pyrimidine 2.30 (CID1542103) (Table 5). Compound 2.28 displayed 
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high antagonism activity on GPR35 (IC50/EC50 = 20.1 nM), however this compound has a 
rhodanine ring. Compounds with a rhodanine ring have been recommended to be 
excluded from libraries screening results due to the misleading potential through various 
chemical effects, as described as Pan Assay Interference Compounds (PAINS).
[11]
 The 
misleading potential resulted from structure reactivity, chelation probability, and 
aggregation. Compound 2.29 is also a potent GPR35 antagonist (IC50/EC50 = 160 nM), 
but we were concerned that the thiourea hydrazone functionality could react in a 
nonselective manner, similar to the rhodanine ring.
[11]
 In addition to these concerns, the 
GPR35 inactive state (R) model has a binding site that appears to be more suitable for 
elongated ligands. For these reasons, benzothiazole 2.1 was selected for this ligand-based 
homology model optimization. Although compound 2.1 has a moderate antagonism 
activity at GPR35 (IC50/EC50 = 0.55 µM), its structural features and conformation could 
be modified to improve on its activity. 
 
Table 5 
 
GPR35 Antagonists 
 
Antagonist Structure IC50/EC50 
2.28 (CID2286812) 
 
20.1 nM 
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Table 5 
(Cont.) 
Antagonist Structure IC50/EC50 
2.29 (CID2745684) 
 
160 nM 
2.1 (CID1231538) 
 
0.55 µM 
2.30 (CID1542103) 
 
2.2 µM 
 
Docking Study 
Docking of benzothiazole 2.1 into this homology model of GPR35 (Figure 25) 
indicated that benzothiazole 2.1 possessed a handful of favorable interaction with the 
binding site. Specifically, residues R4.60(151)
[12]
 and R6.58(240) provide hydrogen 
bonding with the morpholine amide oxygen and the heterobicyclic nitrogen, respectively. 
Residue S7.39(262) provided weak hydrogen bonding with the exocyclic sulfur. Also 
residue Y3.37(101) and Y7.36(259) provide aromatic stacking interactions with the 
39 
 
 
phthalamide and the aryl connected to the thiol, respectively. In spite of the fact that 
benzothiazole 2.1 has moderate potency, these favorite interactions, together with the 
scarcity of GPR35 antagonists, enforced our decision to choose benzothiazole 2.1 as a 
probe for this ligand-based structure-activity relationships study.  
 
 
 
Figure 25. Docking of Benzothiazole 2.1 in the GPR35 Homology Model. 
 
Further scrutiny of the dock of benzthiazole into the homology model of GPR35 
identified additional information.  It was hypothesized that the position of the morpholine 
is important because it blocks the F6.48(230) χ1 g+ → trans rotation. Since the rotation 
of F6.48 is hypothesized to be important for activation of many GPCRs,
[13] 
the position of 
the morpholine ring could be crucial for this ligand to act as an antagonist. Based on the 
model, there were no residues in that area of the binding pocket available for hydrogen 
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bonding so the influence on the toggle switch seems to be solely steric in nature. Thus, 
piperidine 2.2 and pyrrolidine 2.3 were prepared to examine this supposition. The GPR35 
R model suggests that the exocyclic sulfur in benzothiazole 2.1 is only weakly hydrogen 
bonding to S7.39 (262) (S-O distance = 3.4 Å). Oxidation of the sulfur would shorten the 
distance (O-O distance = 2.6 Å) and provided stronger hydrogen bonding. Therefore, 
sulfoxide 2.4 and sulfone 2.5 were synthesized to improve this interaction (Scheme 2.6). 
Due to the chiral nature of the sulfoxide, enantiomers 2.6 and 2.7 were individually 
synthesized (Scheme 2.7). The GPR35 R model implied that the terminal aryl group 
adjacent to the thiol has no influence in the binding pocket other than the aromatic 
stacking interactions. To test that assumption, benzene 2.8 and pyridine 2.9 were 
synthesized (Scheme 2.6). The GPR35 R model suggests that in the heterocyclic core of 
benzothiazole 2.1 the nitrogen can be hydrogen bonded with R6.58(240) but the sulfur 
does not have any discernible interactions. To exploit this, the benzimidazole 2.10 was 
made (Scheme 2.6). Benzimidazole 2.10 may provide a positive potential surface instead 
of negative potential surface of the sulfur near the electron rich region of S7.39 (262). 
The benzylic methylene of benzothiazole 2.1 provided beneficial van der Waals 
interactions. Based on the current model, the S-enantiomer of a benzylic methyl group 
(compound 2.11) will fit nicely into the binding pocket and enhance the predicted van der 
Waals interactions with R6.58(240), whereas the R-enantiomer will have detrimental 
steric clashes (Scheme 2.10).  
Compounds 2.2-2.11 were docked individually into the GPR35 homology model 
inactive state to perceive the binding site interactions. The residues R4.60 and R6.58 
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provide hydrogen bonding interaction for compound 2.1-2.11. The residue S7.39 provide 
hydrogen bonds to the thio ether group in compound 2.1-2.3, 2.8-2.11, and to the oxygen 
in 2.1-2.7 (Table 6). In contrast between GPR35 and other related GPCRs, in GPR35 R 
model the residue R3.36 blocks the movement of F6.48 and H6.52 stacks with F6.48 
from above. Thus, it is possible that the toggle switch for GPR35 is more complex than 
other related GPCRs with three residue required to move to reach the active state. All 
these compounds were synthesized and biologically evaluated.  
Synthesis of GPR35 Antagonists 
The synthesis of this family of compounds was designed so that many diverse 
analogs could be rapidly accessed (Figure 26).  The proposed synthetic route involves the 
opening of phthalic anhydride with commercially available cyclic amines to produce an 
amide and carboxylic acid. The acid will be coupled to the heterobicyclic aryl amine and 
then the thiol will be alkylated with commercially available aryl groups. 
 
 
 
Figure 26. Proposed Synthetic Route for GPR35 Antagonists. 
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The first step in the synthesis was the opening of the phthalic anhydride using the 
amine functionality of morpholine to successfully produce the amide and carboxylic acid. 
The reaction took 4 hours under refluxed temperature to produce the intermediate 2.31 in 
good yield (Figure 27). 
 
 
 
Figure 27. Synthesis of Compound 2.31. 
 
 The following step is the coupling of intermediate 2.31 with 5-amino-2-
mercaptobenzothiazole using N,N'-dicyclohexylcarbodiimide (DCC) to form compound 
2.32. One equivalent of DCC was added to a solution of starting material, N-
hydroxysuccinimide (HOSu), triethylamine (TEA) and 5-amino-2-mercaptobenzothiazole 
in dimethylformamide (DMF). The DCC coupling reaction produced mixture of products 
that did not include the intended product (Figure 28). An alternative procedure was 
suggested which include formation of acyl chloride followed by nucleophilic addition 
elimination reaction (Figure 28). The acyl chloride was prepared using thionyl chloride 
followed by the addition of the 5-amino-2-mercaptobenzothiazole, however, the 
anticipated product was not formed. It was observed that the coupling reaction of 5-
amino-2-mercaptobenzothiazole incorporated some difficulties. As a result another 
synthetic route was proposed.  
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Figure 28. Unsuccessful Trails to Synthesize Compound 2.32. Reagents and conditions: 
(a) 5-amino-2-mercaptobenzothiazole, DMF, HOSu, TEA, DCC, rt., 17 hr; (b) 1) SOCl2, 
DCM 2) 5-amino-2-mercaptobenzothiazole, TEA, DCM, THF. 
 
This route relied on the formation of phthalisoimide ring as substantial 
intermediate that will be reopened with the amine function of the cyclic amines (Figure 
29). The synthetic route to synthesis compound 2.1 was exemplified in Figure 28. The 
synthetic route began with ring-opening of the commercially available phthalic anhydride 
with the amine functionality of 5-amino-2-mercaptobenzothiazole to form benzoate 2.33. 
The resulting product was a good candidate for phthalisoimide ring formation (Figure 
30). This was achieved through treatment of the resulting product with acetic anhydride 
and triethylamine to produce phthalisoimide 2.34.
[14] 
Although the phthalisoimide ring 
seems to be unstable, the product of this reaction was precipitated out of cold water with 
a yield of 90%. Following the same protocol, the phthalisoimide ring was opened by the 
amine function of morpholine to generate 2.35. The reaction was straightforward; 
however, formation of the morpholinium salt decreases the yield and required special 
treatment. The resulting products were purified by recrystalization in 46% yield. The last 
step is a typical SN2 reaction of the thiol moiety and 4-chloro benzyl chloride, however 
the benzothiazole 2.1 was isolated in low yield (Scheme 2.3).  
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Figure 29. Phthalisoimide Ring. 
 
 
 
Figure 30. Synthesis of Benzothiazole 2.1. Reagents and conditions: (a) THF, 30 °C, 17 
hr, 89%; (b) (CH3CO)2O, TEA, 1,4 Dioxane, rt, 17 hr, 90%; (c) morpholine, THF, reflux, 
2 hr, HCl, 46%; (d)  p-ClBzCl, DMF, NaH, 4 hr, 32%. 
 
 
The preceding synthetic route was followed to synthesize analog 2.2 and 2.3. As 
previously mentioned, analogs 2.2 and 2.3 have piperidine or pyrrolidine as replacement 
of morpholine, respectively. Opening the phthalisoimide ring with piperidine or 
pyrrolidine produced intermediates 2.36 and 2.37 in 24% and 31% respectively (Figure 
31).  
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Figure 31. Synthesis of Intermediate 2.36 and 2.37. 
 
In spite of the lower yields, formation of iminium salts, and the demand for 
satisfactory yield to access analogs 2.4, 2.5, 2.6, and 2.7, following the same synthetic 
route to synthesize analog 2.9 encountered with some difficulties. Analog 2.9 has a 
pyridine as a replacement of aryl group on the lead compound. Following the established 
synthetic route proved to be unsuccessful due to the presence of the weakly basic 
nitrogen. After various experimental conditions had been attempted, another pathway was 
devised. This modified route enabled us to access many different structures with good to 
satisfactory yields.   
The synthetic route to synthesize compounds 2.1-2.3, and 2.8-2.10 initiated with 
ring-opening of phthalic anhydride with the amine functionality of 6-amino-2-
mercaptobenzothiazole to form acid 2.12 in 96% yield or with 5-amino-2-
mercaptobenzoimidazole to form compound 2.19, also in good yield (95%) (Figure 32). 
Addition of thiol 2.12 and 4-chlorobenzyl chloride, benzyl chloride, or 4-(chloromethyl) 
pyridine hydrochloride to a solution of sodium hydroxide in ethanol successfully 
produced thioethers 2.13, 2.15, and 2.17 respectively.
[15]
 The subsequent step is the 
formation of the phthalisoimide ring using acetic anhydride and triethylamine.
[14]
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Phthalisoimide intermediates 2.14, 2.16, and 2.18 were produced in 91%, 96%, and 87% 
yields respectively. The phthalisoimide rings were opened using morpholine, piperidine, 
or pyrolidine to produce final analogs 2.1, 2.2, 2.3, 2.8, and 2.9. Analog 2.10 was 
synthesized following the same protocol using 5-amino-2-mercaptobenzoimidazole as 
starting substrate through intermediates 2.19, 2.20, and 2.21. 
 
  
 
Figure 32. General Synthetic Route. Reagents and conditions: (a) THF, 30 °C, 17 hr; (b) 
NaOH, EtOH, 0 °C to rt, ArCH2Cl, 17 hr; (c) (CH3CO)2O, TEA, 1,4 dioxane, rt, 17 hr; 
(d) R2NH, THF, 50-35°C, 15 hr.   
 
Oxidation of the exocyclic sulfur of the benzothiazole 2.1 was accomplished to 
generate racemic sulfoxide 2.4, sulfone 2.5, and the individual enantiomers of sulfoxide 
2.4 (Figure 33). Racemic sulfoxide 2.4 was synthesized in 82% yield using an equimolar 
amount of substrate and oxidizing agent meta-chloroperoxybenzoic acid (mCPBA). The 
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same approach was employed to synthesize sulfone 2.5 using excess of mCPBA. The 
individual sulfoxide enantiomers (2.6 and 2.7) were synthesized using cumene 
hydroperoxide, titanium tetraisopropoxide and the respective enantiomer of diethyl 
tartrate.
[16]
  
 
 
 
Figure 33. Oxidation of the Exocyclic Sulfur. Reagents and conditions: (a) mCPBA, 
CH2Cl2, 0 °C to rt., 3 hr, 82%; (b) mCPBA, CH2Cl2, 0 °C to rt., 5 hr, 83%; (c) (+) DET, 
Ti(Oi-Pr)4, C6H5C(CH3)2OOH, DIPEA, toluene, 2 h, 59%; (d) (-) DET, Ti(Oi-Pr)4, 
C6H5C(CH3)2OOH, DIPEA, toluene, 2 h, 53%.   
 
The retrosynthesis analysis to synthesize the S-enantiomer of compound 2.11 is 
demonstrated in Figure 34. The synthesis proposed to use nucleophilic substitution (SN2) 
to set the stereo center using commercially available (S)-4-chloro-α-methyl-benzyl 
alcohol and thiol 2.35 (Figure 30). Formation of a good leaving group is a requisite for 
successful SN2 reaction.  
48 
 
 
 
 
Figure 34. Retrosynthesis Analysis of Compound 2.11. 
 
 
Conversion of the hydroxyl group to triflate group was done using triflic 
anhydride and pyridine (Figure 35). Replacement of hydroxyl group by triflate group was 
completely achieved as indicated by the NMR, nevertheless the substitution of triflate 
leaving group by nucleophilic sulfur was unsuccessful. (S)-4-chloro-α-methyl-benzyl 
alcohol was then reacted with mesityl chloride to form mesityl leaving group. The 
reaction was done at -20 ºC and completed in one hour at the same temperature. 
Replacement of OH with OMs was achieved also as indicated by the NMR; however the 
SN2 reaction was ineffective (Figure 35).  
Various experiments were attempted including in situ replacement of OH with Cl 
using (S)-4-chloro-α-methyl-benzyl alcohol (Figure 35). (S)-4-chloro-α-methyl-benzyl 
alcohol reacted with oxalyl chloride at 0 °C followed by addition of compound 2.35.  
However the intended product was not observed. Also (R)-4-chloro-α-methyl-benzyl 
alcohol was subjected to Mitsunobu reaction condition, triphenylphosphine (PPh3) and 
diethyl azodicarboxylate (DEAD); likewise the desired product was not achieved (Figure 
36).  
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Figure 35. Conversion of OH to a Good Leaving Group. Reagents and conditions: (a) 
Tf2O, pyridine, DCM, rt, 76%; (b) MsCl, TEA, DCM, -20 °C; (c) (COCl)2, TEA, DMF, 
DCM, 0 °C. 
 
 
 
Figure 36. Mitsunobu Condition to Synthesize Compound 2.11. Reagents and conditions: 
(a) PPh3, DIAD, THF, 0°C to rt. 
 
Due to the ineffectuality of the SN2 reaction on the secondary position, synthesis 
of compound 2.11 followed a slightly different synthetic route (Figure 37). Compound 
2.11 was synthesized in a racemic fashion with this study and plans for an 
enantioselective synthesis could be developed based on the activity of racemic 2.11. The 
synthesis began with nucleophilic addition of the commercially available 1-phenylethyl 
mercaptan to 2-chloro-6-nitrobenzothiazole to form nitrobenzothiazole 2.22 in 80% yield. 
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The nitro group was then reduced to amine 2.23 through catalytic hydrogenation. The 
resulting primary amine was used to open phthalic anhydride to produce the intended 
product 2.24 in high yield (98%). The following step is the formation of the 
phthalisoimide ring 2.25 in 70% yield which was reopened by morpholine to successfully 
produce analog 2.11 in 76% yield (Figure 37). 
 
 
 
Figure 37. Reagents and Conditions. (a) NaH, DMF, 5 hr, 80%; (b) H2, Pd/C, EtOH, 17 
hr, 89%; (c) phthalic anhydride, THF, 30 °C, 17 hr, 98%; (d) (CH3CO)2O, TEA,1,4 
dioxane, rt, 17 hr, 70%; (e) morpholine, THF, 35 °C, 15 hr, 76%. 
 
-Arrestin Assay 
The activities of the synthesized analogs as antagonists at GPR35 was examined 
using β-arrestin-2-recruitment assay. U2OS cells permanently expressing HA-GPR35a  
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and arr2-GFP (UGPR35β)  were utilized for most experiments. Cells were plated onto 
coverslips that were placed in 24 well plates.  Cells were maintained at 37 C in 5% CO2 
until ready for experiments (80-85% confluent). Cells were washed once with Hank's 
buffered salt solution (HBSS) before drug application and experiments were performed in 
HBSS.  Cells were incubated with drug for 40 minutes at room temperature then fixed 
with 4% paraformaldehyde for 20 minutes. Glass coverslips were mounted on slides and 
were imaged on a (Nikon E800) fluorescence microscope using a 40 X oil objective and 
488 nm excitation for GFP.  
Data Analysis of -Arrestin Assay 
arr2-GFP aggregates were quantified by using the ImageJ software 
(http://rsbweb.nih.gov/ij/). Concentration-effect curves for agonist-mediated receptor 
activation were analyzed by nonlinear regression techniques using GraphPad Prism 5.0 
software (GraphPad) and data were fitted to sigmoidal dose-response curves to obtain 
IC50 (Figure 38). 
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Figure 38. Concentration-effect Curves for GPR35 Antagonists. 
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Results and Discussion 
The evaluations of the analogs comprise considerable information (Table 6). The 
fact that piperidine 2.2 and pyrolidine 2.3 are devoid of activity as GPR35 antagonists 
indicate that there is likely to be a strong interaction between the oxygen of the 
morpholine ring and a residue in the binding site in this region. We assumed that the 
morpholine ring affected the toggle switch, but without any hydrogen bonding to lock the 
ring in place.  
 
Table 6 
 
Biological Results 
 
Antagonist Structure IC50(CI range) 
2.1 
 
4.6 (1.8-12) 
2.2 
 
>30 
2.3 
 
>30 
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Table 6 
(Cont.) 
Antagonist Structure IC50(CI range) 
2.4 
 
13 (4.0-45) 
2.5 
 
5.2 (2.2-13) 
2.6 
 
>30 
2.7 
 
>30 
2.8 
 
7.2 (2.3-23) 
2.9 
 
>30 
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Table 6 
(Cont.) 
Antagonist Structure IC50(CI range) 
2.10 
 
>30 
2.11 
 
17 (5.6-54) 
 
Oxidation of the exocyclic sulfur to sulfoxide 2.4 and sulfone 2.5 decreased the 
activity as an antagonist; we assumed that this small detrimental activity was perhaps due 
to electronic effect rather than unfavorable binding site interaction. The sulfoxide 
enantiomers 2.6 and 2.7 are inactive and this is probably due to a combination of steric 
and electronic effects. Replacement of the aryl group connected to sulfur with pyridine in 
compound 2.9 was done to examine the influence of the aryl group on the binding pocket. 
Compound 2.9 was found to be inactive GPR35 antagonist which is an indication that the 
basicity of the nitrogen of the pyridine ring produced unfavorable negative potential 
surface. The same scenario exists when the cyclic sulfur is replaced with nitrogen in 
benzimidazole 2.10. These results provided us with key binding pocket interactions 
which will be utilized in the further development of the model of GPR35 and also will be 
used as guidance for designing novel antagonists for GPR35.  
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The paramount aim of this work is to gain a precise understanding of the function 
and pharmacology of GPR35 receptor by means of pharmacological tools.  These tools 
include mainly accessing a potent and selective GPR35 ligand and building a 
computational modeling of the GPR35 receptor. Although the outcomes of this study lack 
a potent compound with antagonist activity at GPR35 receptor, the study provides a 
delicate understanding on the binding pocket of the GPR35 inactive state.  The toggle 
switch occurrence required strong hydrogen-bonding with the residue to lock the 
antagonist in place. This piece of information assists in developing and refining the 
homology model of the GPR35 receptor. Likewise, the homology model refining 
includes the residue at the binding site of terminal aryl group connected to the thiol. This 
area was found to be, depending on the results, preferred a positively potential surface. 
The refinement also included the region of S7.39 (262) in view of the fact that the 
positively charged surface was found to be unfavored.  The initial structure-activity 
relationships study is used to further refine a homology model of GPR35 receptor. The 
SAR provides us with precise key binding pocket interactions which are used as a 
foundation in the refinement process of the GPR35 homology model. This model will 
serve as a research tools or basis for designing and developing novel drugs.  
Experimental Procedures 
All anhydrous reactions were performed in oven dried glassware under a nitrogen 
atmosphere.  All commercial reagents and solvents were used without further 
purification. Chromatographic purification was performed using silica gel (60 Å, 32-
63μm). Analytical thin-layer chromatography (TLC) was performed on SiO2 plates and 
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visualizing by UV irradiation at 254 nm. NMR spectra were recorded in CDCl3, DMSO-
d6, methanol-d4, or acetone-d6 using JEOL ECA spectrometer (500 MHz for 
1
H, 125 
MHz for 
13
C). All 
1
H NMR experiments are reported in δ units, parts per million (ppm) 
downfield of TMS, and were measured relative to the signals for chloroform (7.26 ppm), 
DMSO (2.50 ppm), methanol (3.31 ppm), or acetone (2.05 ppm). All 
13
C NMR spectra 
were reported in ppm relative to the signals for chloroform (77 ppm), DMSO (39.5 ppm), 
methanol (49 ppm), acetone (29.8 ppm) and. Coupling constants, J, are reported in hertz 
(Hz) and multiplicities are listed as singlet (s), doublet (d), triplet (t), doublet of doublets 
(dd), triplet of doublets (td), quintet (quint), multiplet (m), etc. High resolution mass 
spectra were acquired on a Thermo Fisher Scientific LTQ Orbitrap XL MS system using 
electrospray ionization (ESI). 
 Phthalic anhydride (1.00 g, 6.75 mmol) was added to a solution of 
mercaptobenzothiazole (1.23 g, 6.75 mmol) in THF (50 mL) and the mixture was stirred 
at 30 °C for 17 hours (Figure 39). THF was then evaporated under reduced pressure and 
the product was purified by recrystallization out of ethanol/ water mixture to yield yellow 
crystal (2.13 g, 96%). 
 
 
                                                                                                                     2.12 
 
Figure 39. Synthesis of Compound 2.12. 
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1
H NMR (500 MHz, DMSO-d6) δ 13.05 (br. s, 1H), 10.52 (s, 1H), 8.13 (d, J = 1.7 Hz, 
1H), 7.89 (dd, J = 1.1, 7.4 Hz, 1H), 7.66 (td, Jd = 1.4, Jt = 7.7 Hz, 1H), 7.56 - 7.61 (m, 
2H), 7.54 (d, J = 8.0 Hz, 1H), 7.27 (d, J = 9.2 Hz, 1H). 
13
C NMR (126 MHz, DMSO-d6) δ 189.5, 168.0, 167.9, 139.2, 137.7, 136.9, 132.3, 
130.42, 130.37, 130.1, 130.0, 128.3, 119.7, 113.0, 112.6.  
HRMS (ESI): C15H11N2O3S2 [M+H]
+
, Calculated: 331.02111, Found: 331.01990. 
 To a solution of NaOH (0.23 g, 5.68 mmol) in ethanol (40 mL) under 0 °C was 
added compound 2.12 (1.25 g, 3.78 mmol) and 4-chlorobenzyl chloride (0.61 g, 3.78 
mmol). The mixture was stirred at 0 °C for 30 minutes and then at room temperature for 
17 hours (Figure 40). The ethanol was removed under reduced pressure and water (20 
mL) was added to the residue. The aqueous layer was washed with dichloromethane (3 X 
20 mL) and then acidified to pH~2 using hydrochloric acid (1 M). The aqueous layer was 
then placed on an ice bath and the resultant precipitate was collected by vacuum 
filtration, washed with water, and dried on vacuum to yield the desired product as pale 
yellow powder (1.63 g, 95%). 
 
 
                  2.12                                                                                             2.13 
 
Figure 40. Synthesis of Compound 2.13. 
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1
H NMR (500 MHz, DMSO-d6) δ 10.62 (s, 1H), 8.48 (d, J = 2.3 Hz, 1H), 7.90 (dd, J = 
1.1, 7.4 Hz, 1H), 7.84 (d, J = 8.6 Hz, 1H), 7.67 (td, Jd = 1.1, Jt = 7.4 Hz, 1H), 7.55 - 7.62 
(m, 3H), 7.52 (d, J = 8.6 Hz, 2H), 7.40 (d, J = 8.6 Hz, 2H), 4.63 (s, 2H). 
13
C NMR (126 MHz, DMSO-d6) δ 168.1, 167.9, 164.5, 149.2, 139.2, 137.1, 136.5, 
135.9, 132.7, 132.4, 131.5 (2C), 130.4, 130.1, 130.1, 129.1 (2C), 128.4, 121.7, 119.5, 
112.1, 36.4. 
HRMS (ESI): C22H16ClN2O3S2 [M+H]
+
, Calculated: 455.02909, Found: 455.02704. 
 Following a reported procedure,
[14]
 a mixture of acetic anhydride (0.70 mL, 0.75 
g, 7.39 mmol) and triethylamine (2.06 mL, 1.49 g, 14.77 mmol) was added dropwise to a 
suspension of compound 2.13 (1.12 g, 2.46 mmol) in dry 1,4 dioxane (20 mL). The 
suspension turned to clear yellowish solution upon completion of the addition. The 
reaction mixture was allowed to stir at room temperature for 17 hours (Figure 41). The 
mixture was poured into ice and product was precipitated instantly. The product was 
collected by filtration, washed with water, sodium bicarbonate, water, and dried on 
vacuum to yield the desired product as a yellow powder (0.98 g, 91%). 
 
                       2.13                                                                                        2.14 
 
Figure 41. Synthesis of Compound 2.14. 
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1
H NMR (500 MHz, CDCl3) δ 7.96 - 8.00 (m, 3H), 7.84 (d, J = 1.7 Hz, 1H), 7.81 (dd, J 
= 2.9, 5.2 Hz, 2H), 7.51 (dd, J = 2.3, 8.6 Hz, 1H), 7.40 (d, J = 8.6 Hz, 2H), 7.29 (d, J = 
8.6 Hz, 2H), 4.58 (s, 2H). 
13
C NMR (126 MHz, CDCl3) δ 167.5, 167.4 (2C), 152.5, 135.9, 134.9, 134.7 (2C), 
133.8, 131.7, 130.6 (2C), 129.0 (2C), 128.0, 124.9, 124.0 (2C), 121.9, 119.5 (2C), 37.0. 
HRMS (ESI): C22H14ClN2O2S2 [M+H]
+
,Calculated: 437.01852, Found: 437.01680. 
 Morpholine (1.19 mL, 1.17 g, 13.48 mmol) was added to a solution of compound 
2.14 (0.98 g, 2.25 mmol) in THF (30 mL) and the mixture was stirred at 50 °C for 2 
hours then at 35 °C for 15 hours (Figure 42). THF was removed under reduced pressure 
and water (20 mL) was added to the resultant residue. The mixture was acidified to pH~2 
using hydrochloric acid (1 M). The product was extracted with ethyl acetate (3 X 40 mL), 
washed with water (4 X 25 mL), and dried over sodium sulfate. The product was 
crystallized during solvent evaporation under reduced pressure to yield 1.19 g of pale 
yellow crystal (99%).   
 
  
                  2.14                                                                               2.1                                
 
Figure 42. Synthesis of Analog 2.1. 
 
1
H NMR (500 MHz, CDCl3) δ 9.52 (s, 1H), 8.31 (d, J = 1.7 Hz, 1H), 7.77 (dd, J = 1.4, 
7.7 Hz, 1H), 7.70 (d, J = 9.2 Hz, 1H), 7.34 - 7.42 (m, 5H), 7.28 (d, J = 8.6 Hz, 2H), 7.14 
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(dd, J = 1.7, 6.9 Hz, 1H), 4.52 (s, 2H), 3.98 (br. s, 1H), 3.70 (br. s, 3H), 3.61 (br. s., 2H), 
3.25 (t, J = 4.9 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 170.7, 165.7, 164.9, 149.7, 136.1, 135.2, 135.0, 134.5, 
133.8, 133.7, 131.1, 130.6 (2C), 129.4, 129.3, 128.9 (2C), 126.1, 121.3, 118.9, 111.8, 
66.7, 66.6, 48.0, 42.6, 37.1. 
HRMS (ESI): C26H23ClN3O3S2 [M+H]
+
, Calculated: 524.08694, Found: 524.08498. 
 Piperidine (0.07 mL, 0.06 g, 0.69 mmol) was added to a solution of compound 
2.14 (0.05 g, 0.11 mmol) in THF (10 mL) and the mixture was stirred at 50 °C for 2 
hours then at 35 °C for 15 hours (Figure 43). THF was removed under reduced pressure 
and water (10 mL) was added to the resultant residue. The mixture was acidified to pH~2 
using hydrochloric acid (1 M). The product was extracted with ethyl acetate (3 X 20 mL), 
washed with water (4 X 15 mL), and dried over sodium sulfate. The product was 
crystallized during solvent evaporation under reduced pressure to yield 0.06 g of yellow 
crystal (100%).  
 
    
                  2.14                                                                                   2.2                           
 
Figure 43. Synthesis of Analog 2.2. 
 
 
1
H NMR (500 MHz, CDCl3) δ 9.59 (s, 1H), 8.40 (d, J = 1.7 Hz, 1H), 7.87 (dd, J = 1.7, 
7.4 Hz, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.40 - 7.48 (m, 3H), 7.38 (d, J = 8.6 Hz, 2H), 7.28 
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(d, J = 8.6 Hz, 2H), 7.19 (dd, J = 1.7, 6.9 Hz, 1H), 4.53 (s, 2H), 3.88 (br. s, 1H), 3.61 (br. 
s, 1H), 3.16 (br. s, 2H), 1.59 (br. s., 3H), 1.44 (br. s., 3H).  
13
C NMR (126 MHz, CDCl3) δ 170.2, 165.6, 164.7, 149.6, 136.1, 135.2, 134.9, 134.8, 
133.5, 133.1, 131.1, 130.5 (2C), 129.9, 129.1, 128.8 (2C), 125.8, 121.3, 118.8, 111.7, 
48.7, 43.0, 37.0, 26.2, 25.6, 24.3. 
HRMS (ESI): C27H25ClN3O2S2 [M+H]
+
, Calculated: 522.10767, Found: 522.10489. 
 Pyrrolidine (0.06 mL, 0.05 g, 0.69 mmol) was added to a solution of compound 
2.14 (0.05 g, 0.11 mmol) in THF (10 mL) and the mixture was stirred at 50 °C for 2 
hours then at 35 °C for 15 hours (Figure 44). THF was removed under reduced pressure 
and water (10 mL) was added to the resultant residue. The mixture was acidified to pH~2 
using hydrochloric acid (1 M). The product was extracted with ethyl acetate (3 X 20 mL), 
washed with water (4 X 15 mL), and dried over sodium sulfate. The product was 
crystallized during solvent evaporation under reduced pressure to yield 0.06 g of yellow 
crystal (99%).  
 
 
2.14                                                                               2.3 
 
Figure 44. Synthesis of Analog 2.3. 
 
 
1
H NMR (500 MHz, CDCl3) δ 9.81 (s, 1H), 8.44 (d, J = 1.7 Hz, 1H), 7.94 - 7.97 (m, 1H), 
7.80 (d, J = 9.2 Hz, 1H), 7.50 - 7.53 (m, 2H), 7.48 (dd, J = 2.3, 8.6 Hz, 1H), 7.39 (d, J = 
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8.6 Hz, 2H), 7.31 (d, J = 3.4 Hz, 1H), 7.30 (d, J = 8.6 Hz, 2H), 4.55 (s, 2H), 3.65 (t, J = 
6.9 Hz, 2H), 3.20 (t, J = 6.6 Hz, 2H), 1.94 (quin, J = 6.3 Hz, 2H), 1.87 (quin, J = 6.3 Hz, 
2H). 
13
C NMR (126 MHz, CDCl3) δ 170.4, 166.0, 164.6, 149.6, 136.0, 135.8, 135.6, 135.0, 
133.6, 133.3, 131.0, 130.7 (2C), 129.8, 129.2, 128.9 (2C), 126.3, 121.3, 119.2, 111.9, 
49.4, 46.1, 37.1, 25.9, 24.6. 
HRMS (ESI): C26H23ClN3O2S2 [M+H], Calculated: 508.09202, Found: 508.08904. 
 To a solution of compound 2.1 (0.10 g, 0.19 mmol) in CH2Cl2 (12 mL) at 0 °C 
was added a solution of 70-75% mCPBA (0.033 g, 0.19 mmol) in CH2Cl2 (4 mL) drop 
wise (Figure 45). The ice bath was removed and reaction mixture was stirred at room 
temperature until the starting material was completely consumed in 3 hours (reaction was 
monitored by TLC). A saturated solution of sodium bicarbonate was added and the 
mixture was stirred for 10 minutes. The CH2Cl2 layer was separated and the aqueous 
layer was extracted with CH2Cl2 (2 X 20 mL). The organic layers were combined, 
washed with aqueous sodium bicarbonate, dried over sodium sulfate, and concentrated on 
vacuum. The product was purified by silica gel column chromatography using a solvent 
system of hexane, ethyl acetate and methanol (78/20/2) to obtain 0.08 g (yield 82%) of a 
white powder. 
1
H NMR (500 MHz, CDCl3) δ 9.81 (br. s, 1H), 8.47 (d, J = 2.3 Hz, 1H), 7.84 (d, J = 8.0 
Hz, 1H), 7.77 (d, J = 6.9 Hz, 1H), 7.52 (d, J = 7.4 Hz, 1H), 7.34 - 7.42 (m, 2H), 7.25 - 
7.30 (m, 1H), 7.23 (br. s., 1H), 7.05 - 7.18 (m, 3H), 4.47 (d, J = 13.2 Hz, 1H), 4.33 (br. s, 
1H),  3.98 (br. s, 1H), 3.75 (br. s, 3H), 3.63 (br. s, 2H), 3.27 (t, J = 4.6 Hz, 2H). 
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13
C NMR (126 MHz, CDCl3) δ 175.0, 170.8, 165.9, 150.1, 136.93, 136.89, 135.0, 134.5, 
133.6, 131.9 (2C), 131.3, 129.4 (2C), 129.0 (2C), 127.1, 126.2, 123.7, 120.0, 112.3, 66.7, 
66.6, 61.9, 48.1, 42.6. 
HRMS (ESI): C26H23ClN3O4S2 [M+H]
+
, Calculated: 540.08185, Found: 540.07997. 
 
 
 2.1                                                                                     2.4 
 
Figure 45. Synthesis of Analog 2.4. 
 
 
 To a solution of compound 2.1 (0.1 g, 0.19 mmol) in CH2Cl2 (12 mL) at 0 °C was 
added a solution of 70-75 % mCPBA (0.12 g, 0.48 mmol)  in CH2Cl2 (4 mL) drop wise 
(Figure 46). The ice bath was removed and reaction mixture was stirred at room 
temperature until the starting material was completely consumed in 5 hours (reaction was 
monitored by TLC). A saturated solution of sodium bicarbonate was added and the 
mixture was stirred for 10 minutes. The CH2Cl2 layer was separated and the aqueous 
layer was extracted with CH2Cl2 (2 X 20 mL). The organic layers were combined, 
washed with aqueous sodium bicarbonate, dried over sodium sulfate, and concentrated on 
vacuum. The product was purified by silica gel column chromatography using a solvent 
system of hexane, ethyl acetate and methanol (76/20/4) to obtain 0.088 g (yield 83%) of a 
whitish paige powder. 
1
H NMR (500 MHz, CDCl3) δ 9.76 (s, 1H), 8.58 (d, J = 1.7 Hz, 1H), 8.04 (d, J = 8.6 Hz, 
1H), 7.83 (dd, J = 1.7, 7.4 Hz, 1H), 7.57 (dd, J = 2.0, 8.9 Hz, 1H), 7.41 - 7.49 (m, 2H), 
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7.26 - 7.31 (m, 4H), 7.20 (dd, J = 1.1, 7.4 Hz, 1H), 4.74 (s, 2H), 3.96 (br. s, 1H), 3.73 (br. 
s, 3H), 3.62 (t, J = 4.6 Hz, 2H), 3.27 (t, J = 5.2 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 170.7, 166.0, 163.7, 149.0, 138.4, 138.3, 135.7, 134.3, 
133.4, 132.6 (2C), 131.5, 129.69, 129.67, 129.3 (2C), 126.3, 125.5, 124.9, 120.9, 111.9, 
66.7 (2C), 60.3, 48.2, 42.6. 
HRMS (ESI): C26H23ClN3O5S2 [M+H]
+
, Calculated: 556.07676, Found: 556.07480. 
 
 
2.1                                                                                                      2.5 
 
Figure 46. Synthesis of Analog 2.5. 
 
 Following a reported procedure,
[15]
 to a suspension of compound 2.1 (0.3 g, 0.57 
mmol) in toluene (15 mL) at 50 °C were added (-) diethyl tartrate (0.01 mL, 0.01 g, 0.05 
mmol) and triisopropoxide (0.006 mL, 0.006 g, 0.02 mmol) (Figure 47). After the 
mixture was stirred for 45 minutes at 50 °C, heat was removed and the mixture allowed 
to warm to room temperature. At this point, N-ethyldiisopropylamine (0.004 mL, 0.003 g, 
0.02 mmol) and cumene hydroperoxide (0.09 mL, 0.09 g, 0.57 mmol) were added. The 
mixture was stirred until conversion of most of the starting material to product was 
observed by TLC (about an hour). A saturated solution of sodium bicarbonate (15 mL) 
was added and the product was extracted with ethyl acetate (3 X 30 mL). The organic 
layers were combined, washed with water (2 X 20 mL), dried with sodium sulfate, and 
concentrated on vacuum. The product was purified by column chromatography using a 
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solvent system of hexane, ethyl acetate and methanol (78/20/2) to obtain 0.18g (yield 
59%) of a white powder. 
 
 
2.1                                                                                                      2.6 
 
Figure 47. Synthesis of Analog 2.6. 
 
 
1
H NMR (500 MHz, CDCl3) δ 9.81 (br. s, 1H), 8.47 (s, 1H), 7.84 (d, J = 8.0 Hz, 1H), 
7.77 (d, J = 6.9 Hz, 1H), 7.52 (d, J = 7.4 Hz, 1H), 7.34 - 7.43 (m, 2H), 7.26 - 7.31 (m, 
1H), 7.24 (br. s., 1H), 7.07 - 7.18 (m, 3H), 4.48 (dd, J = 4.0, 13.2 Hz, 1H), 4.33 (br. s, 
1H), 3.98 (br. s, 1H), 3.76 (br. s, 3H), 3.64 (br. s, 2H), 3.27 (t, J = 4.6 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 175.0, 170.8, 165.9, 150.1, 136.93, 136.89, 135.0, 134.5, 
133.6, 131.9 (2C), 131.3, 129.4 (2C), 129.0 (2C), 127.1, 126.2, 123.7, 120.0, 112.3, 66.7, 
66.6, 61.9, 48.1, 42.6. 
HRMS (ESI): C26H23ClN3O4S2 [M+H]
+
, Calculated: 540.08185, Found: 540.07994. 
 Following a reported procedure,
[15]
 to a suspension of compound 2.1 (0.30 g, 0.57 
mmol) in toluene (15 mL) at 50 °C were added (+) diethyl tartrate (0.01 mL, 0.01 g, 0.05 
mmol) and triisopropoxide (0.006 mL, 0.006 g, 0.02 mmol) (Figure 48). After the 
mixture was stirred for 45 minutes at 50 °C, heat was removed and the mixture allowed 
to warm to room temperature. At this point, N-ethyldiisopropylamine (0.004 mL, 0.003 g, 
0.02 mmol) and cumene hydroperoxide (0.09 mL, 0.09 g, 0.57 mmol) were added. The 
mixture was stirred until conversion of most of the starting material to product was 
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observed by TLC (about an hour). A saturated solution of sodium bicarbonate (15 mL) 
was added and the product was extracted with ethyl acetate (3 X 30 mL). The organic 
layers were combined, washed with water (2 X 20 mL), dried with sodium sulfate, and 
concentrated on vacuum. The product was purified by column chromatography using a 
solvent system of hexane, ethyl acetate and methanol (78/20/2) to obtain 0.16 g (yield 
53%) of a white powder. 
 
 
          2.1                                                                            2.7 
 
Figure 48. Synthesis of Analog 2.7. 
 
 
1
H NMR (500 MHz, CDCl3) δ 9.81 (br. s, 1H), 8.47 (s, 1H), 7.84 (d, J = 8.0 Hz, 1H), 
7.77 (d, J = 6.9 Hz, 1H), 7.52 (d, J = 7.4 Hz, 1H), 7.34 - 7.44 (m, 2H), 7.26 - 7.31 (m, 
1H), 7.24 (br. s., 1H), 7.05 - 7.17 (m, 3H), 4.48 (d, J = 13.2 Hz, 1H), 4.33 (br. s, 1H), 
3.98 (br. s, 1H), 3.76 (br. s, 3H), 3.64 (br. s, 2H), 3.27 (d, J = 4.6 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 175.0, 170.8, 165.9, 150.1, 136.9, 136.9, 135.0, 134.5, 
133.6 (2C), 131.9 (2C), 131.3, 129.4 (2C), 129.0, 127.1, 126.2, 123.7, 120.0, 112.3, 66.7, 
66.6, 61.9, 48.1, 42.6. 
HRMS (ESI): C26H23ClN3O4S2 [M+H]
+
, Calculated: 540.08185, Found: 540.07990. 
 To a solution of NaOH (0.02g, 0.45 mmol) in ethanol (5 mL) under 0 °C was 
added compound 2.12 (0.10 g, 0.30 mmol) and benzyl bromide (0.05 g, 0.30 mmol). The 
mixture was stirred at 0 °C for 30 minutes and then at room temperature for 17 hours 
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(Figure 49). The ethanol was removed under reduced pressure and water (15 mL) was 
added to the residue. The aqueous layer was washed with dichloromethane (3 X 15 mL) 
and then acidified to pH~2 using hydrochloric acid (1 M). The aqueous layer was then 
placed on an ice bath and the resultant precipitate was collected by vacuum filtration, 
washed with water, and dried on vacuum to yield the desired product as a pale yellow 
powder (0.10 g, 77%).   
 
 
                     2.12                                                                                   2.15 
 
Figure 49. Synthesis of Compound 2.15. 
 
 
1
H NMR (500 MHz, DMSO-d6) δ 13.07 (br. s, 1H), 10.56 (s, 1H), 8.45 (d, J = 1.7 Hz, 
1H), 7.86 (dd, J = 1.1, 7.4 Hz, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.64 (td, Jd = 1.1, Jt = 7.4 
Hz, 1H), 7.52 - 7.59 (m, 3H), 7.46 (d, J = 7.4 Hz, 2H), 7.32 (td, Jd = 1.7, Jt = 6.9 Hz, 2H), 
7.23 - 7.27 (m, 1H), 4.60 (s, 2H). 
13
C NMR (126 MHz, DMSO-d6) δ 168.1, 167.9, 164.8, 149.3, 139.3, 137.1, 137.0, 
135.8, 132.3, 130.4, 130.1, 130.0, 129.6 (2C), 129.1 (2C), 128.4, 128.2, 121.7, 119.5, 
112.1, 37.3. 
HRMS (ESI): C22H17N2O3S2 [M+H]
+
, Calculated: 421.06806, Found: 421.06649. 
 Following a reported procedure,
[1]
 a mixture of acetic anhydride (0.02 mL, 0.02 g, 
0.21 mmol) and triethylamine (0.06 mL, 0.04 g, 0.43 mmol) was added drop wise to a 
suspension of compound 2.15 (0.03 g, 0.07 mmol) in dry 1,4 dioxane (6 mL). The 
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suspension turned to clear solution upon completion of the addition. The reaction mixture 
was allowed to stir at room temperature for 17 hours (Figure 50). The mixture was 
poured into ice and the product was precipitated instantly. The product was collected by 
filtration, washed with water, sodium bicarbonate solution, water, and dried on vacuum to 
obtain the desired product as a pale yellow powder (0.027 g, yield 96%). 
 
 
    2.15                                                                                     2.16 
 
Figure 50. Synthesis of Compound 2.16. 
 
 
1
H NMR (500 MHz, CDCl3) δ 7.93 - 8.02 (m, 3H), 7.78 - 7.86 (m, 3H), 7.49 (dd, J = 1.7, 
8.6 Hz, 1H), 7.45 (d, J = 7.4 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 7.29 (d, J = 7.4 Hz, 1H), 
4.62 (s, 2H). 
13
C NMR (126 MHz, CDCl3) δ 168.1, 167.4 (2C), 152.6, 136.1, 135.9, 134.7 (2C), 
131.7, 129.2 (2C), 128.9 (2C), 127.89, 127.95, 124.9 (2C), 124.0 (2C), 121.8, 119.4, 
37.8. 
HRMS (ESI): C22H15N2O2S2 [M+H]
+
, Calculated: 403.05749, Found: 403.05574. 
 Morpholine (0.02 mL, 0.02 g, 0.22 mmol) was added to a solution of compound 
2.16 (0.015 g, 0.037 mmol) in THF (6 mL) and the mixture was stirred at 50 °C for 2 
hours then at 35 °C for 15 hours (Figure 51). THF was removed under reduced pressure 
and water (10 mL) was added to the resultant residue. The mixture was acidified to pH~2 
using hydrochloric acid (1 M) and the product was extracted with ethyl acetate (3 X 15 
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mL). All organic layers were combined, washed with water (4 X 15 mL), dried over 
sodium sulfate, and concentrated under reduced pressure. The product was precipitated 
by addition of cold hexane to yield 0.018 g of white yellowish crystal (100%).  
 
 
 2.16                                                                                      2.8 
 
Figure 51. Synthesis of Analog 2.8. 
 
 
1
H NMR (500 MHz, CDCl3) δ 9.22 (s, 1H), 8.38 (d, J = 1.7 Hz, 1H), 7.83 (dd, J = 1.7, 
6.9 Hz, 1H), 7.77 (d, J = 9.2 Hz, 1H), 7.42 - 7.50 (m, 4H), 7.37 (dd, J = 2.3, 8.6 Hz, 1H), 
7.27 - 7.35 (m, 3H), 7.22 (dd, J = 1.7, 7.4 Hz, 1H), 4.58 (s, 2H), 3.97 (br. s, 1H), 3.66 (br. 
s, 3H), 3.58 (t, J = 4.6 Hz, 2H), 3.24 (t, J = 4.6 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 170.5, 165.8, 165.6, 150.0, 136.3, 136.1, 134.9, 134.3, 
133.7, 131.3, 129.6, 129.5, 129.3 (2C), 128.8 (2C), 127.9, 126.2, 121.5, 118.8, 111.9, 
66.7 (2C), 48.0, 42.6, 37.9. 
HRMS (ESI): C26H24N3O3S2 [M+H]
+
, Calculated: 490.12591, Found: 490.12318. 
 To a solution of NaOH (0.03g, 0.76 mmol) in ethanol (6 mL) under 0 °C was 
added compound 2.12 (0.13 g, 0.38 mmol) and 4-(chloromethyl)pyridine hydrochloride 
(0.06 g, 0.38 mmol). The mixture was stirred at 0 °C for 30 minutes and then at room 
temperature for 17 hours (Figure 52). The ethanol was removed under reduced pressure 
and water (20 mL) was added to the residue. The aqueous layer was washed with 
dichloromethane (3 x 20 mL) and then acidified to pH~2 using hydrochloric acid (1 M). 
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The aqueous layer was then placed on an ice bath and the resultant precipitate was 
collected by vacuum filtration, washed with water, and dried on vacuum to yield the 
desired product as a pale yellow powder (0.15 g, 94%).    
 
  
2.12                                                                                  2.17 
 
Figure 52. Synthesis of Compound 2.17. 
 
 
1
H NMR (500 MHz, DMSO-d6) δ 12.99 (br.s, 1H), 10.63 (s, 1H), 8.73 (d, J = 6.3 Hz, 
2H), 8.46 (d, J = 1.7 Hz, 1H), 7.94 (d, J = 6.3 Hz, 2H), 7.85 (dd, J = 1.1, 7.4 Hz, 1H), 
7.78 (d, J = 8.6 Hz, 1H), 7.58 - 7.65 (m, 2H), 7.51 - 7.57 (m, 2H), 4.80 (s, 2H). 
13
C NMR (126 MHz, DMSO-d6) δ 168.1, 167.9, 163.4, 149.0, 144.0 (2C), 139.2, 137.3, 
136.1, 132.4, 130.4, 130.15, 130.07, 128.3, 127.0 (3C), 121.8, 119.6, 112.2, 35.8. 
HRMS (ESI): C21H16N3O3S2 [M+H]
+
, Calculated: 422.06331, Found: 422.06170. 
 A mixture of acetic anhydride (0.07 mL, 0.07 g, 0.71 mmol) and triethylamine 
(0.2 mL, 0.14 g, 1.42 mmol) was added drop wise to a suspension of compound 2.17 
(0.10 g, 0.24 mmol) in dry 1,4 dioxane (6 mL). The suspension turned to clear pale 
yellowish solution upon completion of the addition. The reaction mixture was allowed to 
stir at room temp for 17 hours (Figure 53). The mixture was poured into ice and product 
was precipitated instantly. The product was collected by filtration, washed with water, 
sodium bicarbonate solution, water, and dried on vacuum to obtain the desired product as 
a yellow powder (0.08 g, yield 87%). 
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                         2.17                                                                                       2.18 
 
Figure 53. Synthesis of Compound 2.18. 
 
 
1
H NMR (500 MHz, CDCl3) δ 8.57 (d, J = 6.3 Hz, 2H), 7.95 - 8.01 (m, 3H), 7.85 (d, J = 
1.7 Hz, 1H), 7.82 (dd, J = 2.9, 5.2 Hz, 2H), 7.51 (dd, J = 2.3, 8.6 Hz, 1H), 7.39 (d, J = 5.2 
Hz, 2H), 4.58 (s, 2H). 
13
C NMR (126 MHz, CDCl3) δ 167.4 (2C), 166.7, 152.4, 150.2 (3C), 145.8, 136.0, 134.7 
(3C), 131.7, 128.2, 125.0, 124.04 (2C), 124.01, 122.0, 119.5, 36.1. 
HRMS (ESI): C21H14N3O3S2 [M+H]
+
, Calculated: 404.05274, Found: 404.05149. 
 Morpholine (0.03 mL, 0.03 g, 0.30 mmol) was added to a solution of compound 
2.18 (0.02 g, 0.05 mmol) in THF (6 mL) and the mixture was stirred at 50 °C for 2 hours 
then at 35 °C for 15 hours (Figure 54). THF was removed under reduced pressure and 
water (10 mL) was added to the resultant residue. The mixture was acidified to pH~2 
using hydrochloric acid (1 M) and the product was extracted with ethyl acetate (3 X 15 
mL). All organic layers were combined, washed with water (4 X 15 mL), dried over 
sodium sulfate, and concentrated under reduced pressure. The product was crystallized by 
addition of cold hexane to yield 0.024 g of pale yellowish crystal (99%).   
1
H NMR (500 MHz, CDCl3) δ 9.82 (s, 1H), 8.54 (d, J = 6.3 Hz, 2H), 8.23 (d, J = 2.3 Hz, 
1H), 7.69 (d, J = 6.9 Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.37 (d, J = 1.7 Hz, 2H), 7.35 (d, 
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J = 2.3 Hz, 1H), 7.26 - 7.33 (m, 2H), 7.07 (d, J = 6.9 Hz, 1H), 4.50 (s, 2H), 3.97 (br. s., 
1H), 3.75 (br. s., 2H), 3.65 (br. s, 3H), 3.25 (t, J = 4.6 Hz, 2H). 
13
C NMR (126 MHz, CHLOROFORM-d) δ 170.5, 165.6, 164.3, 150.2 (2C), 149.8, 
145.9, 136.5, 135.1, 134.2, 133.6, 131.4, 129.7, 129.6, 126.3, 124.1 (2C), 121.7, 118.9, 
111.9, 66.7 (2C), 48.1, 42.6, 36.2. 
HRMS (ESI): C25H23N4O3S2 [M+H]
+
, Calculated: 491.12116, Found: 491.11949.      
 
                         2.18                                                                                                     2.9 
 
Figure 54. Synthesis of Analog 2.9. 
 
 Phthalic anhydride (0.20 g, 1.35 mmol) was added to a solution of 5-amino-2-
mercaptobenzoimidazole (0.22 g, 1.35 mmol) in THF (20 mL) and the mixture was 
stirred at room temperature for 17 hours (Figure 55). THF was then evaporated under 
reduced pressure and the product was precipitated out of ethanol/ water mixture (0.40 g, 
yield 95%). 
 
 
                                                                                                                            2.19 
 
Figure 55. Synthesis of Compound 2.19. 
73 
 
 
1
H NMR (500 MHz, DMSO-d6) δ 12.96 (br. s, 1H), 12.42 (s, 2H), 10.34 (br. s., 1H), 7.82 
- 7.85 (m, 1H), 7.79 (d, J = 1.7 Hz, 1H), 7.62 (dt, Jd = 1.1, Jt =  7.4 Hz, 1H), 7.49 - 7.56 
(m, 2H), 7.23 (dd, J = 1.7, 8.6 Hz, 1H), 7.04 (d, J = 8.6 Hz, 1H). 
13
C NMR (126 MHz, DMSO-d6) δ 168.6, 168.0, 167.7, 139.4, 135.4, 132.8, 132.2, 
130.6, 130.0, 129.9, 128.8, 128.3, 115.1, 109.8, 101.5. 
HRMS (ESI): C15H12ClN3O3S [M+H]
+
, Calculated: 314.05994, Found: 314.05894. 
 To a solution of NaOH (0.02 g, 0.48 mmol) in ethanol (5 mL) at 0 °C was added 
compound 2.19 (0.10 g, 0.32 mmol) and 4-chlorobenzyl chloride (0.05 g, 0.32 mmol). 
The mixture was stirred at 0 °C for 30 minutes and then at room temperature for 17 hours 
(Figure 56). The ethanol was removed under reduced pressure and water (20 mL) was 
added to the residue. The aqueous layer was washed with dichloromethane (3 X 15 ml) 
and then acidified to pH~2 using hydrochloric acid (1 M). The aqueous layer was then 
placed on ice bath and the resultant precipitate was collected by vacuum filtration, 
washed with water, and dried on vacuum to yield the desired product as a yellowish white 
powder (0.09 g, 66%).    
 
 
                       2.19                                                                                                         2.20 
 
Figure 56. Synthesis of Compound 2.20. 
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1
H NMR (500 MHz, DMSO-d6) δ 12.98 (br. s, 1H), 12.51 (br. s, 1H), 10.29 (s, 1H), 8.02 
(s, 1H), 7.87 (dd, J = 1.1, 7.4 Hz, 1H), 7.65 (td, Jd = 1.1, Jt = 7.4 Hz, 1H), 7.53 - 7.60 (m, 
2H), 7.46 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.6 Hz, 2H), 7.27 (br. s, 2H), 4.54 (s, 2H). 
13
C NMR (126 MHz, DMSO-d6) δ 168.1, 167.6, 139.6, 137.7, 132.4, 132.2 (2C), 131.2 
(5C), 130.6, 130.0, 129.8, 129.0 (4C), 128.3 (2C), 35.0. 
HRMS (ESI): C22H17ClN3O3S [M+H]
+
, Calculated: 438.06791, Found: 438.06628. 
 A mixture of acetic anhydride (0.02 mL, 0.02 g, 0.21 mmol) and triethylamine 
(0.06 mL, 0.04 g, 0.41 mmol) was added drop wise to a suspension of compound 2.20 
(0.03 g, 0.07 mmol) in dry 1,4 dioxane (6 mL) (Figure 57). The suspension turned to 
clear yellowish solution upon completion of the addition. The reaction mixture was 
allowed to stir at room temp for 17 hours. The mixture was poured into ice and product 
was precipitated instantly. The product was collected by vacuum filtration, washed with 
water, sodium bicarbonate solution, water, and dried on vacuum to obtain the desired 
product as paige powder (0.028 g, yield 97%). 
 
 
                               2.20                                                                                           2.21 
 
Figure 57. Synthesis of Compound 2.21. 
 
 
1
H NMR (500 MHz, CDCl3) δ 7.97 (dd, J = 2.9, 5.2 Hz, 2H), 7.80 (dd, J = 3.1, 5.4 Hz, 
2H), 7.49 - 7.62 (m, 2H), 7.33 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 7.21 (dd, J = 
1.7, 8.6 Hz, 1H), 4.52 (s, 2H). 
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13
C NMR (126 MHz, CDCl3) δ 167.9 (2C), 151.1, 135.5, 134.5 (4C), 133.7, 131.9 (2C), 
130.4 (2C), 129.0 (2C), 126.1, 123.9 (3C), 121.5 (2C), 36.4. 
HRMS (ESI): C22H15ClN3O2S [M+H]
+
, Calculated: 420.05735, Found: 420.05586. 
 Morpholine (0.02 mL, 0.02 g, 0.21 mmol) was added to a solution of compound 
2.21 (0.02 g, 0.04 mmol) in THF (6 mL) and the mixture was stirred at 50 °C for 2 hours 
then at 35 °C for 15 hours (Figure 58). THF was removed under reduced pressure and 
water (15 mL) was added to the resultant residue. The mixture was acidified to pH~2 
using hydrochloric acid (1 M). The product was extracted with ethyl acetate (3 X 20 mL), 
washed with water (4 X 15 mL), and dried over sodium sulfate. The product was 
crystallized from ethyl acetate/ hexane, filtered and dried under vacuum to obtain 0.017 g 
of a pale yellow product (93%). 
 
 
2.21                                                                                   2.10 
 
Figure 58. Synthesis of Compound 2.10. 
 
 
1
H NMR (500 MHz, CDCl3) δ 10.13 (br. s, 1H), 8.90 (s, 1H), 8.05 (s, 1H), 7.88 (d, J = 
6.9 Hz, 1H), 7.45 - 7.59 (m, 3H), 7.26 - 7.32 (m, 3H), 7.23 (d, J = 8.6 Hz, 2H), 7.04 (s, 
1H), 4.45 (s, 2H), 3.94 (br. s, 1H), 3.63 (br. s, 3H), 3.50 (br. s, 2H), 3.21 (br. s., 2H). 
13
C NMR (126 MHz, CDCl3) δ170.6, 168.0, 165.8, 149.9, 135.6, 134.7, 134.6, 133.9, 
133.5, 132.8, 131.8, 131.4, 130.4 (2C), 129.7, 129.2, 128.9, 128.9 (2C), 126.4, 123.9, 
66.64, 66.61, 48.0, 42.5, 36.3.  
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HRMS (ESI): C26H24ClN4O3S [M+H]
+
, Calculated: 507.12576, Found: 507.12397. 
 To a solution of 1-phenylethyl mercaptan (0.06 g, 0.06 mL, 0.47 mmol) in DMF 
(3 mL) was added 60% NaH (0.02 g, 0.47 mmol) in mineral oil (Caution: 1-Phenylethyl 
mercaptan has an unpleasant odor
[17]
). The mixture stirred for 10 minutes before a 
solution of 2-chloro, 6-nitrobenzothiazole (0.1 g, 0.47 mmol) in DMF (1 mL) was added 
(Figure 59). After 4 hours the complete conversion of starting materials to product was 
observed by TLC (Ethyl acetate: hexane; 10:90%). Water (10 mL) was added to the 
reaction mixture followed by ethyl acetate (30 mL). The organic layer was separated and 
concentrated. Cold hexane was added to precipitate 0.12 g of the product in 80% yield.    
 
 
                                                                                                                                           2.22 
 
Figure 59. Synthesis of Compound 2.22. 
 
1
H NMR (500 MHz, CDCl3) δ 8.64 (d, J = 2.3 Hz, 1H), 8.29 (dd, J = 2.3, 8.6 Hz, 1H), 
7.92 (d, J = 9.2 Hz, 1H), 7.48 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.4 Hz, 2H), 7.29 (t, J = 7.4 
Hz, 1H), 5.23 (q, J = 7.1 Hz, 1H), 1.88 (d, J = 7.1 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 173.4, 157.0, 144.2, 141.3, 135.7, 128.9 (2C), 128.2, 
127.5 (2C), 122.0, 121.5, 117.5, 47.9, 22.7. 
 To a solution of compound 2.22 (0.10 g, 0.32 mmol) in ethanol (10 mL) was 
added 20% Pd/C (0.02 g) and the system was pressurized with a balloon fill with H2. The 
closed system was stirred at 50 °C for 4 hours (Figure 60). The mixture was filtered 
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through celite and washed with ethanol and chloroform. The solvent was evaporated 
under reduced pressure and the product (0.08 g) was carried on to the next step without 
further purification due to the unpleasant odor.   
 
 
2.22                                                                                           2.23 
 
Figure 60. Synthesis of Compound 2.23. 
 
 
 To a solution of compound 2.23 (0.06 g, 0.20 mmol) in THF (20 mL), was added 
phthalic anhydride (0.03 g, 0.20 mmol) and the mixture was stirred at room temperature 
for 17 hours (Figure 61). THF was then evaporated under reduced pressure and the 
product (0.083 g) was taken to the next step without further purification. 
 
 
                                                           2.23                                                                      2.24   
 
Figure 61. Synthesis of Compound 2.24. 
 
 A mixture of acetic anhydride (0.05 mL, 0.05 g, 0.48 mmol) and triethyl amine 
(0.07 mL, 0.05 g, 0.48 mmol) was added drop wise to a suspension of compound 2.24 
(0.073 g, 0.16 mmol) in dry 1,4 dioxane (12 mL). The reaction mixture was allowed to 
stir at room temp for 17 hours (Figure 62). Water (20 mL) was added to the reaction 
mixture and the product was extracted with ethyl acetate (3 X 20 mL). The organic layers 
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were combined and washed with sodium bicarbonate solution, water, dried over 
anhydrous Na2SO4, and evaporated to dryness. A yield of 0.045 g was obtained and was 
carried on to the next step without further purification.  
 
 
                           2.24                                                                         2.25 
 
Figure 62. Synthesis of Compound 2.25. 
 
 
 Morpholine (0.05 mL, 0.05 g, 0.58 mmol) was added to a solution of compound 
2.25 (0.04 g, 0.1 mmol) in THF (10 mL) and the mixture was stirred at 50 °C for 3 hours 
then at 35 °C for 15 hours (Figure 63). THF was removed under reduced pressure and 
water (10 mL) was added to the resultant residue. The mixture was acidified to pH~2 
using hydrochloric acid (1 M). The product was extracted with ethyl acetate (3 X 20 mL), 
washed with water (4 X 10 mL), and dried over sodium sulfate. The solvent was then 
evaporated and the crude mixture purified by column chromatography to obtain 0.036 g, 
yield 67%. 
 
 
                              2.25                                                                                                  2.11 
 
Figure 63. Synthesis of Analog 2.11. 
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1
H NMR (500 MHz, CDCl3) d 9.00 (s, 1H), 8.40 (d, J = 2.3 Hz, 1H), 7.88 (dd, J = 1.7, 
6.9 Hz, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.49 - 7.56 (m, 2H), 7.47 (d, J = 8.0 Hz, 2H), 7.35 - 
7.38 (m, 1H), 7.33 (d, J = 8.0 Hz, 2H), 7.26 - 7.29 (m, 2H), 5.11 (q, J = 6.9 Hz, 1H), 3.92 
(br. s, 1H), 3.68 (br. s, 3H), 3.55 (br. s, 2H), 3.22 (t, J = 4.6 Hz, 2H), 1.84 (d, J = 6.9 Hz, 
3H). 
13
C NMR (126 MHz, CDCl3) δ 170.4, 165.5, 165.3, 150.2, 141.9, 136.6, 134.8, 134.1, 
133.6, 131.5, 129.8, 129.7, 128.8 (2C), 127.9, 127.5 (2C), 126.3, 121.8, 118.7, 111.9, 
66.8 (2C), 48.0, 47.8, 42.5, 22.8. 
HRMS (ESI): C27H26N3O3S2 [M+H]
+
, Calculated: 504.14156, Found: 504.13915. 
NMR Spectra 
 
MA-I-208-PROTON-1.jdf
13 12 11 10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
0.980.962.071.061.010.980.960.78
 
Figure 64. 
1
H NMR Spectra of Compound 2.12. 
 
 
Water 
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Figure 65. 
13
C NMR Spectra of Compound 2.12. 
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Figure 66. 
1
H NMR Spectra of Compound 2.13. 
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Figure 67. 
13
C NMR Spectra of Compound 2.13. 
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Figure 68. 
1
H NMR Spectra of Compound 2.14. 
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Figure 69. 
13
C NMR Spectra of Compound 2.14. 
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Figure 70. 
1
H NMR Spectra of Compound 2.1. 
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Figure 71. 
13
C NMR Spectra of Compound 2.1. 
 
 
MA-I-155-FINAL-1.jdf
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Figure 72. 
1
H NMR Spectra of Compound 2.2. 
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MA-I-155-13C-delta-1.jdf
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
2
4
.3
9
2
5
.7
0
2
6
.3
13
7
.0
8
4
3
.1
1
4
8
.8
2
1
1
1
.7
8
1
1
8
.9
2
1
2
1
.4
7
1
2
5
.9
2
1
2
8
.9
2
1
3
0
.6
2
1
3
1
.2
0
1
3
5
.0
2
1
3
5
.3
2
1
3
6
.2
3
1
4
9
.7
7
1
6
4
.8
3
1
6
5
.7
3
1
7
0
.3
4
 
 
Figure 73. 
13
C NMR Spectra of Compound 2.2. 
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Figure 74. 
1
H NMR Spectra of Compound 2.3. 
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MA-I-92-13C-delta-2.jdf
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Figure 75. 
13
C NMR Spectra of Compound 2.3. 
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Figure 76. 
1
H NMR Spectra of Compound 2.4. 
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MA-I-217-13C-delta-1.jdf
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Figure 77. 
13
C NMR Spectra of Compound 2.4. 
 
 
MA-I-158-proton-1.jdf
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1.951.983.872.001.023.762.061.021.011.000.960.86
 
 
Figure 78. 
1
H NMR Spectra of Compound 2.5. 
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MA-I-158-13C-delta-1.jdf
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Figure 79. 
13
C NMR Spectra of Compound 2.5. 
 
 
MA-I-220#17-dry-1.jdf
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Figure 80. 
1
H NMR Spectra of Compound 2.6. 
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MA-I-220#17-13c-delta-1.jdf
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Figure 81. 
13
C NMR Spectra of Compound 2.6. 
 
 
MA-I-221-cry#2-1.jdf
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Figure 82. 
1
H NMR Spectra of Compound 2.7. 
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MA-I-221-13C-delta-1.jdf
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Figure 83. 
13
C NMR Spectra of Compound 2.7. 
 
 
MA-II-70-DMSO-1.jdf
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Figure 84. 
1
H NMR Spectra of Compound 2.15. 
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MA-II-70-13C-delta-1.jdf
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Figure 85. 
13
C NMR Spectra of Compound 2.15. 
 
 
MA-II-71-1H-1.jdf
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Figure 86. 
1
H NMR Spectra of Compound 2.16. 
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MA-II-71-13C-delta-1.jdf
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Figure 87. 
13
C NMR Spectra of Compound 2.16. 
 
 
MA-I-71#2-1.jdf
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Figure 88. 
1
H NMR Spectra of Compound 2.8. 
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MA-I-71-13C-delta-1.jdf
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Figure 89. 
13
C NMR Spectra of Compound 2.8. 
 
 
MA-I-223-WATER-1.jdf
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Figure 90. 
1
H NMR Spectra of Ccompound 2.17. 
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MA-I-226-13C-delta-1.jdf
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Figure 91. 
13
C NMR Spectra of Compound 2.17. 
 
 
MA-I-227-CHCl3-1.jdf
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Figure 92. 
1
H NMR Spectra of Compound 2.18. 
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MA-I-227-13C-delta-1.jdf
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Figure 93. 
1
H NMR Spectra of Compound 2.18. 
 
 
MA-II-231-H-delta-1.jdf
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Figure 94. 
1
H NMR Spectra of Compound 2.9. 
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MA-I-231-13C-delta-1.jdf
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Figure 95. 
13
C NMR Spectra of Compound 2.9. 
 
 
MA-II-66-1.jdf
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Figure 96. 
1
H NMR Spectra of Compound 2.19. 
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MA-II-66-13C-delta-1.jdf
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Figure 97. 
13
C NMR Spectra of Compound 2.19. 
 
 
MA-II-67-SA-H-1.jdf
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Figure 98. 
1
H NMR Spectra of Compound 2.20. 
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MA-II-67-C13-delta-1.jdf
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Figure 99. 
13
C NMR Spectra of Compound 2.20. 
 
 
MA-II-68-1H-1.jdf
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Figure 100. 
1
H NMR Spectra of Compound 2.21. 
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Figure 101. 
13
C NMR Spectra of Compound 2.21. 
 
 
MA-II-69#3-1.jdf
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1.974.961.032.000.872.062.952.860.970.930.900.72
 
 
Figure 102. 
1
H NMR Spectra of Compound 2.10. 
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Figure 103. 
13
C NMR Spectra of Compound 2.10. 
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Figure 104. 
1
H NMR Spectra of Compound 2.22. 
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Figure 105. 
13
C NMR Spectra of Compound 2.22. 
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Figure 106. 
1
H NMR Spectra of Compound 2.11. 
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Figure 107. 
13
C NMR Spectra of Compound 2.11. 
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CHAPTER III 
 
DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF PYRAZOLE 
DERIVATIVES 
 
Introduction 
Almost two decades ago GPR35 was discovered and classified as an orphan 
GPCR receptor. However, the areas of GPR35 research still lack the basic 
pharmacological tools. These tools necessitate a need to characterize the GPR35 receptor, 
to define the chemistry and biochemistry of this receptor, to elucidate the mechanism of 
action of this receptor, and finally to use this information to explicate the therapeutic 
advantages of this receptor. The key to the pharmacological tool is finding a ligand with 
high potency and selectivity at GPR35 receptor to serve as a research probe. Also of 
importance, GPR35 has been described as a novel therapeutic target due to the 
association of this receptor with the numbers of major diseases and disorders (see 
Chapter I, Introduction). 
In our previous work, benzothiazole 3.20 (Figure 108) was used as a probe for the 
ligand-based homology model optimization. This work provided precise analysis on the 
nature of the residue at binding pocket by means of a structure-activity relationship study. 
The result was used for developing and refining the GPR35 homology model. However, 
the search for potent and selective ligand with antagonist activity at GPR35 was still our 
major aim. Thus, in this chapter we report the design, synthesis, and evaluation of a 
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GPR35 antagonist based on pyrazole 3.19 structure (Figure 109), plus design, synthesis, 
and antimicrobial evaluation of pyrazole derivatives.  
 
Figure 108. GPR35 Antagonist (CID1231538). 
 
Design of GPR35 Antagonists 
Pyrazole 3.19 (Figure 3.2) is the most potent GPR35 antagonist observed to this 
point. This pyrazole was discovered and identified as the best GPR35 antagonist of 
~300,000 compounds assessed in an image-based high-content primary screening 
performed at the Sanford-Burnham Institute Molecular Libraries Probe Production 
Center.
 
 
Figure 109. GPR35 Antagonist (CID2745687). 
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Pyrazole 3.19 displayed high antagonism activity at GPR35, however this 
compound has a thiourea hydrazone functionality. Compounds with rhodanine related 
rings, pyrazolidine rings, activated hydrazones, or compounds with potential Micheal 
acceptors have been recommended to be excluded from libraries screening results,  as 
described as Pan Assay Interference Compounds (PAINS).
[11]
 These compounds were 
recommended to be excluded due to the misleading potential through various chemical 
effects including structure reactivity, chemical instability, chelation, or aggregation. Due 
to the potential chemical instability or resonance probability of thiourea hydrazone 
functionality of pyrazole 3.19, pyrazole 3.19 could adopt a conformational change that 
could lead to the formation of rhodanine related ring (Figure 110). This pyrazolidine ring 
could produce chemical reactivity similar to the rhodanine ring. On account of these 
reasons and concerns, pyrazole 3.19 was selected as a lead for designing new GPR35 
antagonist by avoiding thiourea hydrazone functionality.  
 
 
 
Figure 110. Potential Formation of PAINS Ring. 
 
Pyrazole 3.19 was docked into the GPR35 homology model to predict the 
conformational interactions with the residues at the binding site. Residues R164 and 
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Q3.29(93) provides hydrogen bonding with the ester oxygen of pyrazole 3.19 with N-
H—O distances of 2.6 Å and 2.8 Å, respectively. Q 3.29(93) also provides hydrogen 
bonding to the hydrazone hydrogen with O—H-N distance of 2.9 Å. Residue H6.52(234) 
provides aromatic staking interactions with the difluro aromatic ring (Figure 111).  
 
 
 
Figure 111. Docking and Key Interactions of Pyrazole 3.19 with GPR35. 
 
 
Three different scaffolds were designed based on the core structure of pyrazole 
3.19 (Figure 111). The scaffolds preserve the aryl pyrazole core while the urea 
functionality replaces the thiourea. The first scaffold contained alkene function in place 
of hydrazone. The second scaffold comprised a phenylenediamine ring, whereas the third 
scaffold comprised triazole ring (Figure 112). The designed analogs were docked into the 
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GPR35 homology model inactive state (R) to predict the interaction or the lack of 
interactions with the residues at the binding site. The docking process predicted that the 
phenylenediamine scaffold possessed preferable interaction with the helices of the 
GPR35 model (R).   
 
 
Figure 112. GPR35 Proposed Scaffolds.  
 
Docking of amino pyrazole 3.1 into the homology model of GPR35 (Figure 112) 
indicated that amino pyrazole 3.1 possessed a handful of favorable interaction with the 
binding site. Specifically, residue R164 and Q3.29(93) provides hydrogen bonding with 
carboxylic acid oxygen with N-H—O distances of 2.6 Å and 2.7 Å, respectively. Q 
3.29(93) also provides hydrogen bonding to amine hydrogen with O—H-N distance of 
3.1Å. Residue R(167) and R4.60(151) provide hydrogen bonding with the urea oxygen 
with N-H—O distances of 3.0 Å and 2.8 Å, respectively. Residue H6.52 (234) provides 
aromatic stacking interactions with difluoro aromatic ring (Figure 113).  
109 
 
 
 
Figure 113. Docking and Key Interactions between Pyrazole 3.1 and GPR35. 
 
 
Analogs 3.20-3.31 were proposed based on the docking of amino pyrazole 3.1 
into the GPR35 homology model (Figure 114). Synthesis and biological evaluation of 
these analogs aimed to reach a potent GPR35 antagonist via structure-activity 
relationship studies. This was achieved by varying the urea substituent (analogs 3.20- 
3.26), replacing carboxylic acid with a primary amide (analog 3.27), functionalizing the 
phenylenediamine ring (analog 3.28), replacing pyrazole with pyrrole ring (analog 3.29), 
removing the amino pyrazole function (analog 3.30), and finally addition of methylene 
between the pyrazole and the attached aryl group (analog 3.31). 
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Figure 114. GPR35 Antagonist Analogs. 
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Synthesis of Pyrazole Analogs 
The proposed synthetic route was initiated by examining amino pyrazole 3.1 to 
test the synthetic route and to optimize experimental conditions. Scheme 3.1 exemplified 
the reterosynthetic analysis to synthesize amino pyrazole 3.1. Buchwald-Hartwig cross 
coupling reaction was proposed as main step in this route. Amino pyrazole 3.1 will be 
achieved by deesterification of amino pyrazole 3.32 which will be prepared through 
Buchwald-Hartwig coupling of pyrazole 3.33 and urea 3.4. The Buchwald-Hartwig 
substrate 3.33 would be prepared from the reaction of pyrazole 3.3 with triflic achydride 
under basic condition. Urea 3.4 could be prepared through corbonylation of 1,4 
phenylendiamine and cyclohexylamine using triphosgene (Figure 115).  
The synthetic route initiated with the formation of dimethyl 
ethoxymethylenemalonate 3.15 through a condensation of triethyl ortho formate and 
dimethyl malonate catalyzied by zinc chloride.
[7]
 Addition of 3.15 to a refluxing solution 
of phenylhydrazine 3.16 in water produced pyrazole 3.3 in good yield. Treatment of 3.3 
with triflic anhydride and triethylamine produced triflate 3.33 in 96% yields (Figure 116).  
With triflate 3.33 in hand, the Buchwald-Hartwig reaction was first examined 
using urea 3.4, However, no reaction was taking place and recovery of starting materials 
was observed by the NMR. Many different Buchwald-Hartwig reactions using different 
substrates, ligands, bases, and solvents, resulted in recovery of starting materials or 
formation of unknown products (Figure 117).  In addition to Buchwald-Hartwig 
coupling, Ullmann-type coupling was also attempted using several substrates. However, 
all these attempted found to be unsuccessful (Figure 117). 
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Figure 115. Reterosynthetic Analysis of Amino Pyrazole 3.1. 
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Figure 116. Synthesis of Buchwald-Hartwig Substrate 3.33. Reagents and conditions: (a) 
Ac2O, ZnCl2 100°C-150°C, 17 hr, 82% (b) 3.16, K2CO3, H2O, 120°C, 17 hr, 70% (c) 
Tf2O, TEA, DCM, 30 °C, 3 hr, 96%. 
 
 
 
Figure 117. Coupling Reaction Experiments. Reagents and conditions: 1. R = 
NHCOC6H11, Cs2CO3, Xantphos, Pd(OAc)2, THF, 100 °C; 2. R = NO2, Cs2CO3, 
Xantphos, Pd(OAc)2, toulene, 115 °C; 3. R = NO2, Cs2CO3, Xantphos, Pd(OAc)2, 1,4 
dioxane, 115 °C; 4. R = NHCOC6H11, TEA, PPh3, Pd(OAc)2, DMF, 100 °C; 5. R = H, 
Cs2CO3, Xantphos, Pd(OAc)2, THF, 100 °C; 6. R = H, Cs2CO3, PPh3, Pd(OAc)2, DMF, 
65 °C; 7. R = NH2, TEA, Pd(PPh3)2Cl2, CuI, DMF, 100 °C; 8. R = NH2, Cu, K2CO3, 
H2O, 100 °C; 9. R = H, Cu, K2CO3, H2O, 100 °C; 10. R = NH2, Cu, K2CO3, DMF, 80 °C; 
11. R = NO2, Cu, K2CO3, DMF, 80 °C; 12. R = H, Cu, K2CO3, DMF, 80 °C; 13. R = 
NHCOC6H11, Cu, Cu2O, K2CO3, n-butanol, 130 °C; 14. R = NH2, BuLi, THF, 0 °C - 25 
°C; 15. R = NO2, NaH, DMF, 70 °C; 16. R = NH2, THF, 25 °C; 17. R = NH2, NaH, THF, 
25 °C; 18. R = NH2, HCl (conc.), EtOH, 25 °C; 19. R = H, NaH, THF, 25 °C. 
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Due to the ineffectiveness of Buchwald-Hartwig coupling reactions and Ullmann-
type reactions, nucleophilic attack of the nitrogen of the amine function was suggested to 
attach the nitrogen at position 3 of the pyrazole ring. Scheme 3.3 showed many 
experiments under different conditions including aniline, 4-nitroaniline, or 
phenylenediamine, nevertheless, none of these attempted were successful in achieving the 
desired product. Surprisingly, the products of some of these reactions were found to be 
sulfonamides as confirmed by mass spectroscopy and NMR (Figure 3.8). 
 
 
 
Figure 118. Formation of Sulfonamide. 
 
Due to the unexpected formation of the sulfonamides, replacement of the 
hydroxyl group of pyrazole 3.3 with chlorine instead of triflate was suggested as a 
solution. Reaction of pyrazole 3.3 with phosphorous oxychloride (POCl3), thionyl 
chloride (SOCl2), or aluminum chloride (AlCl3) were found to be ineffectual. Many 
reactions were also attempted, including Finkelstein conditions, which resulted in 
recovery of starting materials (Figure 119). 
Although multiple trails to replace the hydroxyl group of pyrazole 3.3 with 
chlorine failed, the desired product was synthesized using 2 equivalents of phosphorous 
oxychoride and pyridine. A sealed reaction of pyrazole 3.3, phosphorous oxychloride and 
pyridine under 200 °C produced carboxylic acid pyrazole 3.17 instead of the methyl ester 
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(Figure 120). The formation of carboxylic acid believed to be resulted from replacement 
of methyl ester by nucleophilic chloride followed by hydrolysis of the acyl chloride 
during workup to form the carboxylic acid. 
 
 
Figure 119. Replacement of Hydroxyl Group with Chlorine. Reagents: 1. POCl3; 2. 
POCl3, CH3CN; 3. AlCl3, CH3CN; 4. AlCl3, 1,4 dioxane; 5. SOCl2; 6. SOCl2, DMF; 7. 
KCl, acetone; 8. PPh3, Cl3CCN, toluene. 
 
 
Figure 120. Synthesis of Pyrazole 3.17. 
 
 
In order to prepare the first analog to test the validity of initial hypothesis, the 
urea 3.4 prepared using commercially available cyclohexyl isocyanate and 1,4 
phenylenediamine. Coupling of pyrazole 3.17 and urea 3.4 produced analog 3.1 in 82% 
(Figure 121). 
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Figure 121. Synthesis of Pyrazole 3.1. Reagents and conditions: (a) benzene, 27°C, 17 hr, 
93% (b) TEA, THF, 27 °C , 17 hr, 82%. 
 
The activity of analog 3.1 as an antagonist at GPR35 was examined using β-
arrestin-2-recruitment assay performed at Dr. Abood’s lab. This assay revealed that 
compound 3.1 is completely inactive as a GPR35 antagonist. According to this finding, 
esterification of pyrazole 3.1 was suggested to mimic the function of the parent. Pyrazole 
3.1 was subjected to numbers of experimental condition to convert the acid to methyl 
ester; however the conversion was ineffective (Figure 122). 
Compound 3.2 was proposed as alternative solution to the failed esterification of 
pyrazole 3.1 for a number of reasons. Compound 3.2 provided protection of the 
carboxylic acid in the form of an amide instead of unfeasible ester. Compound 3.2 could 
be synthesize easily by the reaction of urea 3.4 with pyrazole 3.18, which was accessed 
from reaction of pyrazole 3.3 with phosphorous oxychloride (Figure 123). 
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Figure 122. Esterification of Pyrazole 3.1. Conditions: 1. (CH3)3SiCHN2, dry MeOH; 2. 
(CH3)3SiCHN2, DMF, dry MeOH; 3. MeOH, H2SO4; 4. MeOH, DCC, DMAP; 5. MeI; 6. 
(i) POCl3 (ii) MeOH. 
 
 
 
 
Figure 123. Synthesis of Pyrazole 3.2. Reagents and conditions: (a) POCl3, pyridine, 200 
°C, 17 hr, 92%; (b) TEA, THF, rt., 30 min, 75%. 
 
Comparable to amino pyrazole 3.1, pyrazole 3.2 was also inactive as a GPR35 
antagonist. This finding supports our initial hypothesis that the thio urea hydrazone is 
perhaps the cause of the antagonism activity at GPR35 receptor. These results proved that 
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this scaffold lacks the active feature as GPR35 antagonist. This approach is the basis to 
discontinue pursing the synthesis of the analogs of this scaffold.  
Although these pyrazoles displayed inactive antagonist activity at GPR35 
receptor, careful literature screening proved that this family of compound is completely 
novel. The novelty of these compounds drove our attention to evaluate their biological 
prosperities. Anti-microbial evaluation of this family of compounds was performed at Dr. 
Cech lab.  
Design, Synthesis, and Anti-microbial Evaluation of 5-substituted 1-Aryl-4-Carboxy 
Pyrazole Derivatives 
 
Methicillin-resistant Staphylococcus aureus (MRSA) remains a serious 
threatening health problem due to the emerging resistance to existing anti-microbial 
drugs. Anti-microbial drug resistance is largely due to the intense use of same family of 
anti-microbial drugs.
[1]
 The scarcity in anti-microbial drugs and limited scaffold urges the 
need for new structural lead with potentially unique mode of action and different 
resistance mechanism.    
In recent years, a nitrogen five-membered heterocyclic ring, pyrazole, has gained 
special consideration as a result of its significant biological properties including anti-
cancer,
[2]
 anti-microbial,
[3]
 anti-bacterial, anti-fungal,
[4]
 and anti-inflammatory.
[5]
 
Although not many natural pyrazoles are existing, pyrazole ring is ubiquitous in many of 
synthetic drugs, for instance the anti-inflammatory drugs Celecoxib and Ramifenazone 
(Figure 124).
[6]
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Figure 124. Anti-inflammatory Drugs Contain Pyrazole Core. 
 
Motivated by these reasons and continuous resistance of anti-microbial drugs, and 
with our curiosity to biologically evaluate these structurally novel pyrazoles compounds, 
we report herein the design, synthesis, and initial structure-activity relationships study of 
this novel pyrazole derivates as potential anti-microbial agents.    
The synthetic route to synthesize compounds 3.1 and 3.2 initiated with the 
formation of dimethylethoxymethylene malonate 3.15 through a condensation of 
dimethylmalonate and triethyl ortho formate catalyzied by zinc chloride (Figure 125).
[7]
 
Addition of 3.15 to a refluxed solution of 2,4-diflourophenylhydrazine (3.16) in water 
produced pyrazole 3.3 in 70% yield.
[8]
 Treatment of pyrazole 3.3 with phosphorous 
oxychloride (POCl3) and pyridine produced intermediate 3.17 after basic workup or 
intermediate 3.18 without the basic workup in 80% and 92% yields respectively. Urea 3.4 
was synthesized in 93% yield by the addition of cyclohexylisocyanate to a solution of 
phenylenediamine in benzene.
[9]
 Nucleaphilic addition of the amine function of urea 3.4 
to intermediates 3.17 or 3.18 produced the final analogs 3.1 (82%) and 3.2 (75%) 
respectively.   
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Figure 125. Synthetic Route of Pyrazoles 3.1 and 3.2. Reagents and conditions: (a) 
CH(EtO)3, Ac2O, ZnCl2 100 °C-150 °C, 17 hr, 82%; (b) 16, K2CO3, H2O, 120 °C, 17 hr, 
70%; (c) POCl3, pyridine, 200 °C, 4 hr, 80%; (d) POCl3, pyridine, 200 °C, 17 hr, 92%; 
(e) 4, TEA, THF, 27°C , 17 hr, 82%; (f) 4, TEA, THF, rt, 30 min, 75%; (g) benzene, 
27°C, 17 hr, 93% 
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Pyrazole 3.5 was synthesized in 78% yield by the addition of ethyl iodide to a 
solution of pyrazole 3.3 and potassium carbonate in DMF (Scheme 3.10). Addition of 
intermediate 3.18 to a solution of aniline in THF produced pyrazole 3.6 in 93% yield.  
 
 
Figure 126. Synthesis of Pyrazoles 3.5 and 3.6. Reagent and conditions: (a) POCl3, 
Pyridine, 200 °C, 17 hr, 92%; (b) CH3CH2I, K2CO3, DMF, 78%; (c) aniline, TEA, THF, 
rt, 4 hr, 93%. 
 
Synthesized pyrazoles 3.1-3.6 were evaluated for their anti-microbial activity 
using agar diffusion assay. Each compound was suspended in DMSO and diluted with 
Mueller Hinton broth for a final test concentration of 6 and 10 µM of 2% DMSO 
solution. Staphylococcus aureus (SA1199) was added at a standardized CFU/mL 
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concentration and allowed to incubate for 24 hours at 37 °C and turbidity was measured 
at OD 600 nm. The percent growth inhibition was calculated at the concentrations listed 
in Table 3.1. The antimicrobial drug, berberine was used as reference drug (or control) to 
compare the inhibition potency of the synthesized pyrazoles. 
The anti-microbial activities of pyrazoles 3.1-3.6 directed us to conduct an initial 
structure-activity relationships study on pyrazole 3.3 (Figure 127). Diversification of the 
aryl group was done to examine the effect of inductive, electron withdrawing and 
electron donating groups on the antimicrobial activity of the pyrazole. Aryl amine or 
ether functionality at position 5 of pyrazole 3.3 created novel structural pyrazoles. 
Careful literature screening showed that biological evaluation of pyrazole-5-amine 
derivatives has not been explored. Finally, anti-microbial evaluations of 4-carboxylic acid 
pyrazoles are yet to be explored. 
 
 
Figure 127. Structure-activity Relationships of Pyrazole Derivatives.  
 
Pyrazole 3.7 and 3.8 were synthesized using a similar method to the synthesis of 
pyrazole 3.3.
[8]
 Addition of intermediate 3.15 to a solution of phenylhydrazine or 4-
methoxyphenylhydrazine hydrochloride in water produces pyrazoles 3.7 in 81% yield 
and 3.8 in 95% yield (Scheme 3.11). Pyrazole 3.9 was synthesized in 43% yield by the 
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addition of intermediate 3.15 to a cold solution of 4-nitrophenylhydrazine hydrochloride 
and K2CO3 in methanol. 
 
 
 
Figure 128. Diversification of the 1-aryl Pyrazole. (a) K2CO3, H2O, 120°C, 17 hr, 3.7: 
81%, 3.8: 95% (b) K2CO3, EtOH, 0°C to rt, 1 hr, 43% 
 
Replacement of the 2,4-diflourophenyl ring with phenyl or 4-methoxyphenyl 
groups resulted in significant increase in the anti-microbial activity.  Pyrazoles 3.7 and 
3.8 exhibited percent inhibition of 62% and 54% at 6 µM respectively (Table 3.1). Our 
tactic was to examine the effect of substitution of the aryl group of the pyrazole with 
electron withdrawing and electron donating groups on the anti-microbial activity in order 
to select the effective pyazole as a lead for compound development. Thus, pyrazole 3.8 
was selected for further diversification. Addition of benzyl bromide or 4-chlorobenzyl 
chloride to a solution of pyrazole 3.8 and K2CO3 in DMF at 50 °C produces pyrazole 
3.10 (72%) and 3.11 (84%) respectively (Figure 129).   
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Figure 129. Synthesis of 5-substituted Pyrazoles. Reagents and conditions: (a) POCl3, 
pyridine, 200°C, 4 hr, 67% (b) benzyl bromide or 4-chlorobenzyl chloride, K2CO3, DMF, 
50°C, 17 hr, 3.10: 72%, 3.11: 84% (c) aniline or 1,4-phenylenediamine, triethylamine, 
THF, 27 °C, 17 hr, 3.13: 67%, 3.14: 89%.  
 
Treatment of pyrazole 3.8 with POCl3 and pyridine produce pyrazole 3.12 in 67 
% yield (Scheme 3.12). Pyrazole 3.12 was used as intermediate in the synthesis of 
pyrazoles 3.13 and 3.14. Pyrazoles 3.13 in 67% yield and 3.14 in 89% yield were 
synthesized by the addition of intermediate 3.12 to a solution of aniline or 
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phenylenediamine in THF respectively. We also attempted to examine the effect of 
electron deficient aniline at position 5 on the antimicrobial activity of the pyrazole. 
However, reaction of 3.12 with nitroaniline proved to be ineffectual.  
Results and Discussion 
The structure-activity relationships study of the synthesized pyrazoles provides 
considerable information (Table 7). One of the most important findings is that urea 3.4 is 
an inactive anti-microbial agent. This finding determined that the moderate potency of 
compounds 3.1 and 3.2 was due to the pyrazole core. Among the synthesized compounds, 
pyrazoles 3.3, 3.5, 3.7, 3.8, and 3.11 exhibited good anti-microbial activities with 
percentage inhibition of 42%, 47%, 62%, 54% and 48% at 6 µM, respectively. In 
contrast, pyrazoles 3.6, 3.13 and 3.14 exhibited poor anti-microbial activity with 
percentage inhibition of 14%, 18% and 11% at 6 µM, respectively.  
Analysis of the anti-microbial activities showed that the aryl group has slight 
influence on the antimicrobial activity. However, a phenyl group (3.7) and an electron 
donating aryl groups (3.8) slightly increase the anti-microbial activity of the pyrazoles. 
The slight improvement of the anti-microbial activity presumed to be due to increasing 
electron density on the pyrazole core. With exceptional of pyrazole 3.10, pyrazoles with 
an ether function at position 5 of the pyrazole exhibited a significant increase in the anti-
microbial activity of pyrazole derivatives (3.5, 3.11). On the contrary, amine function at 
position 5 decreases the anti-microbial activity drastically (3.13, 3.14). This difference 
could be electronic in nature or due to the potential protonated state of the amine. 
Additionally, while an ester substitution at position 4 of the pyrazole appears to be 
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favorable function, amide substitution at position 4 diminished the anti-microbial activity 
(3.6).  
 
Table 7 
 
Anti-microbial Activity of Pyrazoles 1-14  
 
  % Inhibition at            
Compound ID Structure 6 µM 10 µM 
3.1 
 
30 ±1 18 ± 16
a
 
3.2 
 
42 ±13 42 ±13 
3.3 
 
18 ±2 41±12 
3.4 
 
N.I. N.I. 
3.5 
 
47±9 32±14 
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Table 7 
(Cont.) 
  % Inhibition at            
Compound ID Structure 6 µM 10 µM 
3.6 
 
14±1 N.I. 
3.7 
 
62±3 54±1
a 
3.8 
 
54±1
 
43±3
a 
3.9 
 
40 ±17 8 ±3
a 
3.10 
 
24 ±10 21 ±15
a 
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Table 7 
(Cont.) 
  % Inhibition at            
Compound ID Structure 6 µM 10 µM 
3.11 
 
48±9 47±4
a 
3.12 
 
24±1 12±2
a 
3.13 
 
18 ±12 15±12
a 
3.14 
 
11±8 15±9
a
 
a 
compounds tested at 12 µM; N.I. = no inhibition.  
 
 The initial structure-activity relationships study for a family of pyrazoles that act 
as anti-microbial agents proves that an increase electron density on the pyrazole core has 
a positive influence on the activity. An aryl amine at position 5 should provide greater 
effect on the pyrazole ring than the ether function. However, pyrazoles with an ether 
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function at position 5 are significantly active anti-microbial agents than the 5-amino 
pyrazoles. This perhaps is due to the presence of the carboxylic acid function at position 
4 of the pyrazole ring. Deprotonation of the acid and formation of zwitterion ion with the 
amine function could decrease the solubility of pyrazole 3.13 and 3.14 in the broth. 
However, protection of the acid in the form of an ester is a requisite to validate this 
hypothesis. This initial study presents the design and synthesis of a novel scaffold with 
anti-microbial activity that will serve as a research tools or basis for designing and 
developing novel anti-microbial drugs. 
Experimental Procedures 
All anhydrous reactions were performed in oven dried glassware under a nitrogen 
atmosphere. All commercial reagents and solvents were used without further purification. 
Chromatographic purification was performed using silica gel (60 Å, 32-63μm). 
Analytical thin-layer chromatography (TLC) was performed on SiO2 plates and 
visualizing by UV irradiation at 254 nm. NMR spectra were recorded in CDCl3, 
methanol-d4, acetone-d6, acetonitrile-d3 or DMSO-d6 using JEOL ECA spectrometer (500 
MHz for 
1
H, 125 MHz for 
13
C). Coupling constants, J, are reported in hertz (Hz) and 
multiplicities are listed as singlet (s), doublet (d), triplet (t), doublet of doublets (dd), 
triplet of doublets (td), quintet (quint), multiplet (m), etc. High resolution mass spectra 
were acquired on a Thermo Fisher Scientific LTQ Orbitrap XL MS system using 
electrospray ionization (ESI). 
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 Following a reported procedure,
[7]
 dimethyl malonate (2.10 mL, 2.42 g, 18.3 
mmol) and zinc chloride (0.05 g, 0.37 mmol) were added to stirring solution of triethyl 
ortho formate (2 mL, 1.78 g, 18.3 mmol) in acetic anhydride (10 mL). The reaction 
mixture was stirred at 100 °C for 2 hours and then at 150 °C overnight (Figure 130). The 
reaction mixture was filtered to remove zinc chloride then the solvent was evaporated 
using rotary evaporator under reduced pressure. The mixture was kept on high vacuum 
for overnight to produce reddish brown oil (2.80 g, yield 82%) which is used for the next 
step without further purification. The product matched spectral data from reference 7.
[7] 
 
                                                                                                                                                          3.15 
 
Figure 130. Synthesis of Dimethyllethoxymethylene Malonate 3.15. 
 
 
 Following a reported procedure,
[8]
 dimethylethoxymethylene malonate (3.15) 
(0.94 g, 5.0 mmol) was added to a solution of potassium carbonate (0.69 g, 5.0 mmol) 
and phenyl hydrazine (0.54 g, 5.0 mmol) in water (25 mL) and the reaction mixture was 
refluxed at 120 °C for overnight (Figure 131). The reaction mixture was then cooled and 
washed with ethyl acetate (6 X 15 mL). The aqueous layer was then acidified to pH 2 
using hydrochloric acid (2 N). The resultant precipitate was collected by vacuum 
filtration, washed with water and dried under high vacuum. Recrystallization from 
methanol gives the desired product as pale yellow powder (0.88 g, yield 81%). 
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             3.15                                                                                                                 3.7 
 
Figure 131. Synthesis of Analog 3.7. 
 
 
1
H NMR (500 MHz, CDCl3) δ 9.71 (br. s, 1H), 7.79 (d, J = 7.4 Hz, 2H), 7.77 (s, 1H), 
7.47 (t, J = 8.0 Hz, 2H), 7.33 (t, J = 7.4 Hz, 1H), 3.90 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 166.8, 156.7, 138.5, 137.6, 129.3 (2C), 127.3, 121.4 
(2C), 95.0, 51.8.  
HRMS (ESI): C11H11N2O3[M+H]
+
, Calculated: 219.07697, Found: 219.07575. 
 Dimethylethoxymethylene malonate (3.15) (0.50 g, 2.66 mmol) was added to a 
solution of potassium carbonate (0.73 g, 5.31 mmol) and 4-methoxyphenylhydrazine 
hydrochloride (0.46 g, 2.66 mmol) in water (20 mL) and the reaction mixture was 
refluxed at 120 °C overnight (Figure 132). The reaction mixture was then cooled and 
washed with ethyl acetate (6 X 10 mL). The aqueous layer was then acidified to pH 2 
using hydrochloric acid (2 N). The resultant precipitate was collected by vacuum 
filtration, washed with water and dried over high vacuum. Recrystallization from 
methanol gives the desired product as pale yellow powder (0.62 g, yield 95%). 
1
H NMR (500 MHz, CDCl3) δ 9.59 (br. s, 1H), 7.73 (s, 1H), 7.65 (d, J = 9.2 Hz, 2H), 
6.97 (d, J = 9.2 Hz, 2H), 3.89 (s, 3H), 3.84 (s, 3H).     
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13
C NMR (126 MHz, CDCl3) δ 166.7, 158.7, 156.2, 138.2, 130.7, 123.2 (2C), 114.3 
(2C), 94.7, 55.6, 51.7. 
HRMS (ESI): C12H13N2O4 [M+H]
+
, Calculated: 249.08753, Found: 249.08627. 
 
 
               3.15                                                                                                                 3.8 
 
Figure 132. Synthesis of Analog 3.8. 
 
 
 To a solution of potassium carbonate (0.30 g, 2.12 mmol) and 4-
nitrophenylhydrazine hydrochloride (0.20 g, 1.06 mmol) in methanol (15 mL) at 0 °C, 
was added dimethyl ethoxy methylene malonate (3.15) (0.20 g, 1.06 mmol) and the 
reaction mixture was stirred at room temperature for 2 hours (Figure 133). Methanol was 
removed under reduced pressure. Water (20 mL) was then added and the mixture was 
washed with DCM (4 X 10 mL). The aqueous layer was acidified to pH 2 using 
hydrochloric acid (2N) and resultant precipitate was collected by vacuum filtration, 
washed with water and dried under high vacuum. Recrystallization from methanol gives 
the desired product as dark yellow powder (0.12 g, yield 43%). 
1
H NMR (500 MHz, CDCl3) δ 10.17 (br. s, 1H), 8.34 (d, J = 9.2 Hz, 2H), 8.10 (d, J = 9.2 
Hz, 2H), 7.81 (s, 1H), 3.93 (s, 3H).   
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13
C NMR (126 MHz, CDCl3) δ 145.7, 142.6, 139.6, 125.6, 125.0 (2C), 120.7 (2C), 
118.6, 95.8, 52.1.   
HRMS (ESI): C11H10N3O5 [M+H]
+
, Calculated: 264.06205, Found: 264.06091. 
 
 
            3.15                                                                                                                  3.9 
 
Figure 133. Synthesis of Analog 3.9. 
 
 
 To a solution of methyl 5-hydroxy-1-(4-methoxyphenyl)-1H-pyrazole-4-
carboxylate (3.8) (0.05 g, 0.20 mmol) and potassium carbonate (0.30 g, 0.20 mmol) in 
DMF at room temperature, was added benzyl bromide (0.03 g, 0.02 mL, 0.20 mmol) and 
the mixture was stirred at ambient temperature for 17 hours (Figure 134). Water (15 mL) 
was added and the product was extracted with ethyl acetate (4 X 20 mL). Organic layers 
were combined, washed with water, dried over anhydrous Na2SO4 and evaporated under 
reduced pressure. The crude oil was purified by short silica fritted column and then cold 
ether was added to precipitate the product, 0.053 g, 72% yield.  
1
H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H), 7.36 (d, J = 9.2 Hz, 2H), 7.26 - 7.30 (m, 2H), 
7.23 - 7.25 (m, 1H), 7.17 - 7.21 (m, 2H), 6.89 (d, J = 9.2 Hz, 2H), 5.34 (s, 2H), 3.87 (s, 
3H), 3.83 (s, 3H). 
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13
C NMR (126 MHz, CDCl3) δ 163.0, 159.1, 154.1, 141.6, 135.2, 130.8, 128.9 (2C), 
128.8, 128.5 (2C), 125.3 (2C), 114.1 (2C), 100.8, 55.6, 51.5 (2C). 
HRMS (ESI): C19H19N2O4 [M+H]
+
, Calculated: 339.13448, Found: 339.13304. 
 
 
     3.8                                                                                                            3.10 
 
Figure 134. Synthesis of Analog 3.10. 
 
 
 To a solution of methyl 5-hydroxy-1-(4-methoxyphenyl)-1H-pyrazole-4-
carboxylate (3.8) (0.05 g, 0.20 mmol) and potassium carbonate (0.30 g, 0.20 mmol) in 
DMF, was added 4-chlorobenzyl chloride (0.03 g, 0.20 mmol) and the mixture was 
stirred at 50 °C for 4 hours (Figure 135). Water (15 mL) was added and the product was 
extracted with ethyl acetate (4 X 20 mL). Organic layers were combined, washed with 
water, dried over anhydrous Na2SO4 and evaporated under reduced pressure. The product 
was purified by precipitation out of an ethyl acetate and hexane mixture to obtain 0.064 
g, 84% yield.  
1
H NMR (500 MHz, CDCl3) δ 7.90 (s, 1H), 7.35 (d, J = 9.17 Hz, 2H), 7.20 (d, J = 8.59 
Hz, 2H), 7.10 (d, J = 8.59 Hz, 2H), 6.90 (d, J = 9.17 Hz, 2H), 5.30 (s, 2H), 3.87 (s, 3H), 
3.85 (s, 3H).  
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13
C NMR (126 MHz, CDCl3) δ 163.0, 159.2, 153.9, 141.6, 134.8, 133.7, 130.6, 130.2 
(2C), 128.7 (2C), 125.3 (2C), 114.1 (2C), 100.8, 76.5, 55.7, 51.5. 
HRMS (ESI): C19H18ClN2O4 [M+H]
+
, Calculated: 373.09551, Found: 373.09389. 
 
 
      3.8                                                                                                            3.11 
 
Figure 135. Synthesis of Analog 3.11. 
 
 
 In an oven dried tube, phosphorous oxychloride (0.20 mL, 0.33 g, 2.18 mmol) and 
pyridine (0.18 mL, 0.17 g, 2.18 mmol)  were added to methyl 5-hydroxy-1-(4-
methoxyphenyl)-1H-pyrazole-4-carboxylate (3.8) (0.27 g, 1.09 mmol) at 0 °C and the 
tube was quickly sealed (Figure 136). The mixture was heated for 200 °C for 4 hours. 
The tube was opened and submerged in an ice bath. Then aqueous sodium bicarbonate 
was added carefully to pH 8. The product was extracted by ethyl acetate (3 X 20 mL). 
The organic layers were combined, washed with aqueous sodium bicarbonate (3 X 10 
mL), and dried over anhydrous sodium sulfate. The mixture was concentrated and ether 
was added to precipitate the product, 0.18 g, 67% yield.  
1
H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H), 7.45 (d, J = 9.2 Hz, 2H), 7.03 (d, J = 9.2 Hz, 
2H), 3.88 (s, 3H).  
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13
C NMR (126 MHz, CDCl3) δ 160.4, 156.3, 143.0, 133.1, 130.1, 127.0 (2C), 114.5 
(2C), 110.8, 55.7. 
HRMS (ESI): C11H10ClN2O3 [M+H]
+
, Calculated: 253.03799, Found: 253.03685. 
 
 
                             3.8                                                                                  3.12 
 
Figure 136. Synthesis of Analog 3.12. 
 
 To stirred solution of aniline (0.01 mL, 0.01 g, 0.16 mmol) and triethylamine 
(0.02 mL, 0.01 g, 0.16 mmol) in dry THF was added  5-chloro-1-(4-methoxyphenyl)-1H-
pyrazole-4-carboxylic acid (3.12) (0.04 g, 0.16 mmol) and the mixture was stirred at 27 
°C for overnight (Figure 137). THF was evaporated using rotary evaporator under 
reduced pressure. The residue was dissolved in water (10 mL) and acidified to pH 2 using 
hydrochloric acid (2 N).  The product was extracted with ethyl acetate (3 X 15 mL). The 
organic layers were combined, washed with 5% aqueous hydrochloric acid (4 X 10 mL), 
dried over anhydrous sodium sulfate and evaporated off to dryness using rotary 
evaporator. The resultant solid was suspended in ether and stirred vigorously for 10 min. 
The precipitate was collected by vacuum filtration and further dried on high vacuum to 
obtained 0.03 g, yield 67%. 
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1
H NMR (500 MHz, Acetonitrile-d3) δ 8.48 (br. s., 1H), 8.13 (s, 1H), 7.66 (d, J = 8.6 Hz, 
2H), 7.45 (d, J = 9.2 Hz, 2H), 7.32 - 7.37 (m, 2H), 7.10 - 7.14 (m, 1H), 7.06 (d, J = 9.2 
Hz, 2H), 3.84 (s, 3H). 
13
C NMR (126 MHz, Acetonitrile-d3) δ 160.3, 159.4, 139.9, 138.6, 130.6, 129.2, 128.9 
(2C), 127.3 (2C), 124.2, 120.3 (2C), 115.0, 114.4 (2C), 55.5. 
HRMS (ESI): C17H16N3O3 [M+H]
+
, Calculated: 310.11917, Found: 310.11870. 
 
 
      3.12                                                                                                               3.13 
 
Figure 137. Synthesis of Analog 3.13. 
 
 
 To stirred solution of phenylenediamine (0.02 g, 0.20 mmol) and triethyl amine 
(0.03 mL, 0.02 g, 0.20 mmol) in dry THF (6 mL) was added  5-chloro-1-(4-
methoxyphenyl)-1H-pyrazole-4-carboxylic acid (3.12) (0.05 g, 0.20 mmol) and the 
mixture was stirred at 27 °C overnight (Figure 138). THF was evaporated using rotary 
evaporator under reduced pressure. The residue was dissolved in water (10 mL) and 
acidified to pH 2 using hydrochloric acid (2N).  The product was precipitated upon 
extraction with ethyl acetate. Half of the solvent was evaporated and precipitate was 
collected by vacuum filtration, washed with water, and dried on high vacuum. 0.06 g was 
obtained, 89% yield. 
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1
H NMR (500 MHz, Methanol-D3) δ 8.25 (s, 1H), 7.85 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 
8.6 Hz, 2H), 7.36 (d, J = 9.2 Hz, 2H), 7.10 (d, J = 9.2 Hz, 2H), 3.87 (s, 3H).  
13
C NMR (126 MHz, Methanol-D3) δ 160.65, 160.62, 139.6 (2C), 139.0, 130.2 (2C), 
127.1 (2C), 123.0 (2C), 121.7 (2C), 114.6, 114.1 (2C), 54.8. 
HRMS (ESI): C17H17N4O3 [M+H]
+
, Calculated: 325.13007, Found: 325.12924. 
 
    3.12                                                                                                                3.14 
 
Figure 138. Synthesis of Analog 3.14. 
 
 
 Dimethylethoxymethylene malonate (3.15) (1.50 g, 7.97 mmol) was added to a 
solution of potassium carbonate (1.10 g, 7.97 mmol) and 2,4 diflourophenylhydrazine 
(1.15 g, 7.97 mmol) in water (30 mL) and the reaction mixture was refluxed at 120 °C 
overnight (Figure 139). The reaction mixture was then cooled and washed with ethyl 
acetate (6 X 20 mL). The aqueous layer was then acidified to pH 2 using hydrochloric 
acid (2N). The resultant precipitate was collected by vacuum filtration, washed with 
water and dried under high vacuum. Recrystallization from aqueous methanol gives the 
desired product as pale yellow powder (1.41 g, yield 70%).    
1
H NMR (500 MHz, CDCl3) δ 9.38 (br. s, 1H), 7.80 (s, 1H), 7.43 - 7.52 (m, 1H), 6.97 - 
7.03 (m, 2H), 3.89 (s, 3H). 
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13
C NMR (126 MHz, CDCl3) δ 166.3, 162.9 (dd, J = 10.8, 252 Hz), 157.5, 156.6 (dd, J = 
13.2, 256.7 Hz), 139.7, 129.1 (d. J = 10.8 Hz), 121.0 (dd, J = 3.6, 12 Hz), 112.1 (dd, J = 
3.6, 22.8 Hz), 105.3 (dd, J = 22.8, 26.4 Hz), 94.4. 
HRMS (ESI): C11H9F2N2O3 [M+H]
+
, Calculated: 255.05812, Found: 255.05689. 
 
 
           3.15                                                                                                                 3.3 
 
Figure 139. Synthesis of Analog 3.3. 
 
 
 To a solution of methyl 1-(2,4-difluorophenyl)-5-hydroxy-1H-pyrazole-4-
carboxylate (3.3) (0.02 g, 0.08 mmol) and potassium carbonate (0.01 g, 0.08 mmol) in 
DMF (3 mL) at room temperature, was added iodoethane (0.006 mL, 0.01 g, 0.08 mmol) 
and the mixture was stirred at ambient temperature for 17 hours (Figure 140). Water (15 
mL) was added and the product was extracted with ethyl acetate (4 X 20 mL). The 
organic layers were combined, washed with water, dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. The crude was purified by column chromatography to 
obtain 0.02 g of product as white solid (78% yield).  
1
H NMR (500 MHz, CDCl3) δ 7.95 (s, 1H), 7.39 - 7.46 (m, 1H), 6.96 - 7.03 (m, 2H), 
4.52 (q, J = 7.3 Hz, 2H), 3.84 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H). 
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13
C NMR (126 MHz, CDCl3) δ 162.8 (dd, J = 10.8, 252 Hz), 162.7, 157.1 (dd, J = 13.2, 
256.7 Hz), 156.0, 143.1, 129.7 (dd, J = 10.8 Hz), 121.8 (dd, J = 3.6, 12.0 Hz), 112.0 (dd, 
J = 3.6, 22.8 Hz), 105.1 (dd, J = 22.8, 26.4 Hz), 99.4, 72.2, 51.5, 15.3. 
HRMS (ESI): C13H13F2N2O3 [M+H]
+
, Calculated: 283.08942, Found: 283.08818. 
 
 
          3.3                                                                                                                    3.5 
 
Figure 140. Synthesis of Analog 3.5. 
 
 In an oven dried tube, phosphorous oxychloride (0.15 mL, 0.24 g, 1.57 mmol) and 
pyridine (0.12 mL, 0.12 g, 1.57 mmol)  were added to methyl 1-(2,4-difluorophenyl)-5-
hydroxy-1H-pyrazole-4-carboxylate (3.3) (0.2 g, 0.79 mmol) at 0°C and the tube was 
quickly sealed (Figure 141). The mixture was heated for 200 °C for 4 hours. The tube 
was submerged in an ice bath then aqueous sodium bicarbonate was added carefully to 
pH 8. The product was extracted by ethyl acetate (3 X 20 mL). The organic layers were 
combined, washed with aqueous sodium bicarbonate (3 X 10 mL), dried over anhydrous 
sodium sulfate, and evaporated to dryness using rotary evaporator under reduced 
pressure. The resultant product was dissolved in diethyl ether (20 mL), stirred for 15 
minutes then filtered under vacuum. The ether was evaporated off and the product was 
dried to produce a beige solid (0.16 g, yield 80%).  
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                            3.3                                                                                3.17 
 
Figure 141. Synthesis of Compound 3.17. 
 
 
1
H NMR (500 MHz, Acetone-d6) δ 8.47 (s, 1H), 7.83 (td, Jd = 5.7, Jt = 8.6 Hz, 1H), 7.44 
- 7.50 (m, 1H), 7.32 - 7.38 (m, 1H). 
13
C NMR (126 MHz, Acetone-d6) δ 163.9 (dd, J = 12, 252 Hz), 157.5 (dd, J = 13.2, 
254.3 Hz), 155.9, 143.8, 135.1, 131.1 (d, J = 10.8 Hz), 121.6 (dd, J = 4.8, 13.2 Hz), 112.7 
(dd, J = 3.6, 22.8 Hz), 110.6, 105.4 (dd, J = 24, 27.6 Hz). 
HRMS (ESI): C10H6ClF2N2O2 [M+H]
+
, Calculated: 259.00859, Found: 259.00766. 
 In an oven dried tube, phosphorous oxychloride (0.22 mL, 0.36 g, 2.36 mmol) and 
pyridine (0.19 mL, 0.19 g, 2.36 mmol)  were added to methyl 1-(2,4-difluorophenyl)-5-
hydroxy-1H-pyrazole-4-carboxylate (3.3) (0.3 g, 1.18 mmol) at 0 °C and the tube was 
quickly sealed (Figure 142). The mixture was heated for 200 °C for overnight. The 
reaction mixture was cooled to room temperature then transferred via syringe to a short 
silica fritted column and eluted under vacuum with 150 mL of a mixture of ethyl acetate 
and hexane (2/98). The solvent was evaporated using rotary evaporator under reduced 
pressure followed by high vacuum drying to produce the intended product, light beige 
colored (0.3 g, yield 92%). 
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                           3.3                                                                                  3.18 
 
Figure 142. Synthesis of Compound 3.18. 
 
 
1
H NMR (500 MHz, Acetone-d6) δ 8.43 (s, 1H), 7.83 (td, Jd = 5.7, Jt = 8.6 Hz, 1H), 7.44 
- 7.50 (m, 1H), 7.33 - 7.38 (m, 1H). 
13
C NMR (126 MHz, Acetone-d6) δ 164.9 (dd, J = 10.8, 252 Hz), 158.6, 158.2 (dd, J = 
13.2, 254.3 Hz), 146.2, 135.6, 131.8 (d, J = 10.8 Hz), 122.2 (dd, J = 3.6, 12 Hz), 116.4, 
113.7 (dd, J = 3.6, 22.8 Hz), 106.3 (dd, J = 22.8, 27.6 Hz). 
HRMS (ESI): C10H5Cl2F2N2O [M+H]
+
, Calculated: 276.97470, Found: 276.97362. 
 To stirred solution of aniline (0.02 mL, 0.02 g, 0.18 mmol) and triethyl amine 
(0.03 mL, 0.02 g, 0.18 mmol) in THF (8 mL) was added 5-chloro-1-(2,4-difluorophenyl)-
1H-pyrazole-4-carbonyl chloride (3.18) (0.05 g, 0.18 mmol) and the mixture was stirred 
at room temperature for 1 hour (Figure 143). THF was evaporated off using rotary 
evaporator under reduced pressure. The residue was dissolved in ethyl acetate, washed 
with 5% aqueous HCl (3 X 10 mL), and dried over sodium sulfate. Product was 
precipitated in the ethyl acetate layer during solvent evaporation under reduced pressure. 
The crystals were collected by vacuum filtration (0.06 g, 93% yield). 
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            3.18                                                                                                         3.6 
 
Figure 143. Synthesis of Analog 3.6. 
 
 
1
H NMR (500 MHz, CDCl3) δ 8.26 (s, 1H), 7.94 (br. s., 1H), 7.61 (d, J = 8.02 Hz, 2H), 
7.45 - 7.52 (m, 1H), 7.37 (t, J = 8.02 Hz, 2H), 7.16 (t, J = 7.45 Hz, 1H), 7.02 - 7.10 (m, 
2H).  
13
C NMR (126 MHz, CDCl3) δ 163.7 (dd, J = 10.8, 254.3 Hz), 158.6, 157.5 (dd, J = 
12.00, 256.7 Hz), 142.9, 137.4, 130.3 (dd, J = 9.6 Hz), 129.3 (2C), 128.3, 124.9, 121.6 
(dd, J = 3.6, 12.0 Hz), 120.4 (2C), 115.7, 112.5 (dd, J = 3.6, 22.8 Hz), 105.5 (dd, J = 22.8, 
26.4 Hz). 
HRMS (ESI): C16H11ClF2N3O [M+H]
+
, Calculated: 334.05587, Found: 334.05454.  
 Following a reported procedure,
[9]
 to stirred solution of 1,4-phenylene diamine 
(0.2 g, 1.85 mmol) in benzene was added cyclohexyl isocyanate (0.24 mL, 0.23 g, 1.85 
mmol) and the mixture was stirred at 27 °C under nitrogen atmosphere overnight (Figure 
144). The solid formed was collected by filtration, washed with benzene, collected and 
dried on high vacuum. A white powder product was obtained (0.43 g, yield 93%).  
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                                                                                                                                                        3.4 
 
Figure 144. Synthesis of Urea 3.4. 
 
 
1
H NMR (500 MHz, DMSO-d6) δ 7.75 (s, 1H), 6.98 (d, J = 8.6 Hz, 2H), 6.45 (d, J = 8.6 
Hz, 2H), 5.79 (d, J = 7.4 Hz, 1H), 4.64 (br. s., 2H), 3.34 - 3.48 (m, 1H), 1.72 - 1.83 (m, 
2H), 1.60 - 1.69 (m, 2H), 1.52 (m, 1H), 1.22 - 1.34 (m, 2H), 1.05 - 1.21 (m, 3H). 
13
C NMR (126 MHz, DMSO-d6) δ 155.5, 143.7, 130.3, 120.5 (2C), 114.7 (2C), 48.0, 
33.7 (2C), 25.8, 24.9 (2C). 
HRMS (ESI): C13H20N3O [M+H]
+
, Calculated: 234.16064, Found: 234.15929. 
 To stirred solution of N-(4-aminophenyl)-N-cyclohexyl urea (3.4) (0.09 g, 0.39 
mmol) and triethyl amine (0.05 mL, 0.04 g, 0.39 mmol) in dry THF (10 mL) was added  
5-chloro-1-(2,4-difluorophenyl)-1H-pyrazole-4-carboxylic acid (3.17) (0.10 g, 0.39 
mmol) and the mixture was stirred at 27 °C for overnight (Figure 145). THF was 
evaporated using rotary evaporator under reduced pressure. The residue was dissolved in 
water and acidified to pH 2 using hydrochloric acid (2N).  The product was extracted 
with ethyl acetate (3 X 20 mL). The organic layers were combined, washed with 5% 
aqueous hydrochloric acid (4 X 15 mL), dried over anhydrous sodium sulfate and solvent 
was evaporated off to dryness using rotary evaporator. The resultant paige pinkish solid 
was suspended in ether and stirred vigorously for 10 min. The white precipitate was 
collected by vacuum filtration and further drying on high vacuum to obtain 0.14 g, yield 
82%.  
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      3.17                                   3.4                                                                       3.1 
 
Figure 145. Synthesis of Analog 3.1. 
 
 
1
H NMR (500 MHz, Acetone-d6) δ  9.19 (s, 1H), 8.29 (s, 1H), 7.80 (s, 1H), 7.71 (dt, Jd = 
5.7, Jt = 8.6 Hz, 1H), 7.59 (d, J = 9.2 Hz, 2H), 7.43 (d, J = 9.2 Hz, 2H), 7.37 - 7.42 (m, 
1H), 7.26 - 7.31 (m, 1H), 5.68 (d, J = 8.0 Hz, 1H), 3.53 - 3.61 (m, 1H), 1.84 - 1.92 (m, 
2H), 1.67 (td, Jt = 3.8, Jd = 13.6 Hz, 2H), 1.52 - 1.59 (m, 1H), 1.27 - 1.37 (m, 2H), 1.12 - 
1.21 (m, 3H). 
13
C NMR (126 MHz, Acetone-d6) δ 163.6 (dd, J = 10.8, 250.7 Hz) , 158.5, 157.6 (dd, J = 
13.2, 254.3 Hz), 154.6, 140.8, 137.2, 132.6, 131.1(d, J = 10.8 Hz), 130.8, 122.2(dd, J = 
3.6, 13.2 Hz), 120.7 (2C), 118.1(2C), 115.6, 112.5 (dd, J = 3.6, 22.8 Hz), 105.2 (dd, J = 
24.0, 27.6 Hz), 48.3, 33.4(2C), 25.6 (2C), 24.8. 
HRMS (ESI): C23H24F2N5O3 [M+H]
+
, Calculated: 456.18472, Found: 456.18297.  
 N-(4-aminophenyl)-N-cyclohexyl urea (3.4) (0.04 g, 0.16 mmol) and 
triethylamine (0.03 mL, 0.02 g, 0.16 mmol) were stirred in THF (6 mL) at room 
temperature for 15 min before 5-chloro-1-(2,4-difluorophenyl)-1H-pyrazole-4-carbonyl 
chloride (0.05 g, 0.18 mmol) was added (Figure 146). The consumption of the pyrazole 
was completed after 0.5 hours (monitored by TLC). THF was evaporated off using rotary 
evaporator under reduced pressure. The residue was dissolved in ethyl acetate and 
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washed with 5% aqueous HCl (3 X 10 mL). The product was precipitated in the ethyl 
acetate layer during the washing process. Half of the solvent was removed and a white 
crystal product was collected by vacuum filtration (0.06 g, yield 75%).  
 
 
       3.18                                     3.4                                                                  3.2 
 
Figure 146. Synthesis of Analog 3.2. 
 
 
1
H NMR (500 MHz, DMSO-d6) δ 9.95 (s, 1H), 8.44 (s, 1H), 8.25 (s, 1H), 7.78 (dt, Jd = 
5.70, Jt = 8.60 Hz, 1H), 7.65 - 7.71 (m, 1H), 7.53 (d, J = 8.6 Hz, 2H), 7.35 - 7.39 (m, 1H), 
7.34 (d, J = 8.6 Hz, 2H), 6.02 (d, J = 8.0 Hz, 1H), 3.41 - 3.50 (m, 1H), 1.76 - 1.84 (m, 
2H), 1.62 - 1.69 (m, 2H), 1.49 - 1.58 (m, 1H), 1.25 - 1.36 (m, 2H), 1.10 - 1.24 (m, 3H). 
13
C NMR (126 MHz, DMSO-d6) δ 163.2 (dd, J= 10.8, 250.7 Hz) , 158.7, 157.2 (dd, J = 
13.2, 254.3 Hz), 154.7, 141.3, 137.0, 132.3, 131.5 (d, J = 10.8 Hz), 131.1, 121.8 (dd, J = 
3.6, 12.0 Hz), 121.3 (2C), 118.0 (2C), 115.3, 113.1 (dd, J = 3.6, 22.8 Hz), 105.9 (dd, J = 
24, 27.6 Hz), 47.9, 33.3 (2C), 25.6, 24.7(2C). 
HRMS (ESI): C23H23ClF2N5O2 [M+H]
+
, Calculated: 474.15083, Found: 474.14879.  
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Figure 147. 
1
H NMR Spectra of Compound 3.7. 
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Figure 148. 
13
C NMR Spectra of Compound 3.7. 
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MA-II-179-PROTON-1.jdf
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Figure 149. 
1
H NMR Spectra of Compound 3.8. 
 
 
MA-II-179-CARBON-delta-1.jdf
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Figure 150. 
13
C NMR Spectra of Compound 3.8. 
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MA-II-180-H-1.jdf
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Figure 151. 
1
H NMR Spectra of Compound 3.9. 
 
 
MA-II-180-13C-1.jdf
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Figure 152. 
13
C NMR Spectra of Compound 3.9. 
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MA-II-181-1H-1.jdf
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Figure 153. 
1
H NMR Spectra of Compound 3.10. 
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Figure 154. 
13
C NMR Spectra of Compound 3.10. 
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Figure 155. 
1
H NMR Spectra of Compound 3.11. 
 
 
MA-II-182-13C-delta-1.jdf
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Figure 156. 
13
C NMR Spectra of Compound 3.11. 
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MA-II-186-P-1.jdf
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Figure 157. 
1
H NMR Spectra of Compound 3.12. 
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Figure 158. 
13
H NMR Spectra of Compound 3.12. 
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MA-II-187-C#3-1.jdf
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Figure 159. 
1
H NMR Spectra of Compound 3.13. 
 
 
MA-II-187-13C-delta-1.jdf
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Figure 160. 
13
C NMR Spectra of Compound 3.13. 
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Figure 161. 
1
H NMR Spectra of Compound 3.14. 
 
 
MA-II-188-13C-delta-1.jdf
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Figure 162. 
13
C NMR Spectra of Compound 3.14. 
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MA-II-168-CRYSTAL-1.jdf
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Figure 163. 
1
H NMR Spectra of Compound 3.3. 
 
 
MA-II-168-CRYSTAL13C-1.jdf
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Figure 164. 
13
C NMR Spectra of Compound 3.3. 
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MA-II-177-H-1.jdf
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Figure 165. 
1
H NMR Spectra of Compound 3.5. 
 
 
MA-II-177-13C-delta-1.jdf
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Figure 166. 
13
C NMR Spectra of Compound 3.5. 
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MA-II-168-1H-1.jdf
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Figure 167. 
1
H NMR Spectra of Compound 3.17. 
 
 
MA-II-101-13C-1.jdf
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Figure 168. 
13
C NMR Spectra of Compound 3.17. 
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MA-II-169-acylchloride-1.jdf
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Figure 169. 
1
H NMR Spectra of Compound 3.18. 
 
 
MA-II-169-ACYLCHLORIDE-13C-1.jdf
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Figure 170. 
13
C NMR Spectra of Compound 3.18. 
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MA-II-193-CRYSTAL-1.jdf
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Figure 171. 
1
H NMR Spectra of Compound 3.6. 
 
 
MA-II-193-13C-delta-1.jdf
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Figure 172. 
13
C NMR Spectra of Compound 3.6. 
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MA-II-85-H-1.jdf
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Figure 173. 
1
H NMR Spectra of Compound 3.4. 
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Figure 174. 
13
C NMR Spectra of Compound 3.4. 
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MA-II-105#proton-1.jdf
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Figure 175. 
1
H NMR Spectra of Compound 3.1. 
 
 
MA-II-105-delta-1.jdf
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Figure 176. 
13
C NMR Spectra of Compound 3.1. 
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MA-II-170-HCl EXT. SOLID-1.jdf
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Figure 177. 
1
H NMR Spectra of Compound 3.2. 
 
 
MA-II-170-CARBON-delta-1.jdf
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Figure 178. 
13
C NMR Spectra of Compound 3.2. 
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